<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
    <journal-title-group>
      <journal-title>Genome Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1756-994X</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9563764</article-id>
    <article-id pub-id-type="publisher-id">1119</article-id>
    <article-id pub-id-type="doi">10.1186/s13073-022-01119-6</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CTpathway: a CrossTalk-based pathway enrichment analysis method for cancer research</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Liu</surname>
          <given-names>Haizhou</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Yuan</surname>
          <given-names>Mengqin</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Mitra</surname>
          <given-names>Ramkrishna</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Xu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Long</surname>
          <given-names>Min</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lei</surname>
          <given-names>Wanyue</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Shunheng</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Yu-e</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hou</surname>
          <given-names>Fei</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Eischen</surname>
          <given-names>Christine M.</given-names>
        </name>
        <address>
          <email>christine.eischen@jefferson.edu</email>
        </address>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Jiang</surname>
          <given-names>Wei</given-names>
        </name>
        <address>
          <email>weijiang@nuaa.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.64938.30</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 9911</institution-id><institution>Department of Biomedical Engineering, </institution><institution>Nanjing University of Aeronautics and Astronautics, </institution></institution-wrap>No. 29, Jiangjun Avenue, Nanjing, 211106 Jiangsu Province China </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.265008.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 5843</institution-id><institution>Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, </institution><institution>Thomas Jefferson University, </institution></institution-wrap>233 South 10th St., Philadelphia, PA 19107 USA </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>13</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>14</volume>
    <elocation-id>118</elocation-id>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>4</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>26</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Pathway enrichment analysis (PEA) is a common method for exploring functions of hundreds of genes and identifying disease-risk pathways. Moreover, different pathways exert their functions through crosstalk. However, existing PEA methods do not sufficiently integrate essential pathway features, including pathway crosstalk, molecular interactions, and network topologies, resulting in many risk pathways that remain uninvestigated.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">To overcome these limitations, we develop a new crosstalk-based PEA method, CTpathway, based on a global pathway crosstalk map (GPCM) with &gt;440,000 edges by combing pathways from eight resources, transcription factor-gene regulations, and large-scale protein-protein interactions. Integrating gene differential expression and crosstalk effects in GPCM, we assign a risk score to genes in the GPCM and identify risk pathways enriched with the risk genes.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">Analysis of &gt;8300 expression profiles covering ten cancer tissues and blood samples indicates that CTpathway outperforms the current state-of-the-art methods in identifying risk pathways with higher accuracy, reproducibility, and speed. CTpathway recapitulates known risk pathways and exclusively identifies several previously unreported critical pathways for individual cancer types. CTpathway also outperforms other methods in identifying risk pathways across all cancer stages, including early-stage cancer with a small number of differentially expressed genes. Moreover, the robust design of CTpathway enables researchers to analyze both bulk and single-cell RNA-seq profiles to predict both cancer tissue and cell type-specific risk pathways with higher accuracy.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par4">Collectively, CTpathway is a fast, accurate, and stable pathway enrichment analysis method for cancer research that can be used to identify cancer risk pathways. The CTpathway interactive web server can be accessed here <ext-link ext-link-type="uri" xlink:href="http://www.jianglab.cn/CTpathway/">http://www.jianglab.cn/CTpathway/</ext-link>. The stand-alone program can be accessed here <ext-link ext-link-type="uri" xlink:href="https://github.com/Bioccjw/CTpathway">https://github.com/Bioccjw/CTpathway</ext-link>.</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s13073-022-01119-6.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Pathway enrichment analysis</kwd>
      <kwd>Pathway crosstalk</kwd>
      <kwd>Risk pathway</kwd>
      <kwd>Molecular interaction</kwd>
      <kwd>Network analysis</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
            <institution>National Natural Science Foundation of China</institution>
          </institution-wrap>
        </funding-source>
        <award-id>[61872183] and [62172213]</award-id>
        <principal-award-recipient>
          <name>
            <surname>Jiang</surname>
            <given-names>Wei</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>National Institute of Health/National Cancer Institute</institution>
        </funding-source>
        <award-id>R01CA177786, R01CA236853, and P30CA056036</award-id>
        <principal-award-recipient>
          <name>
            <surname>Eischen</surname>
            <given-names>Christine M.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par41">Over 15 years, significant efforts have been made to annotate the functions of individual genes and construct higher order functional knowledgebases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, it still remains quite challenging to systematically interpret biological meaning from the expression changes of thousands of genes in a specific model system, such as disease versus control. To determine this, a routinely used method is the screening of differentially expressed genes (DEGs) followed by pathway enrichment analysis (PEA).</p>
    <p id="Par42">PEA methods could be categorized into four generations [<xref ref-type="bibr" rid="CR3">3</xref>]. First-generation methods (e.g., DAVID [<xref ref-type="bibr" rid="CR4">4</xref>], WebGestalt [<xref ref-type="bibr" rid="CR5">5</xref>], and several others [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]) usually conduct over-representation analysis (ORA) using a hypergeometric or Fisher’s exact test to assess whether the number of input DEGs is significantly higher than that of the genes expected by chance. However, these ORA methods have several limitations. Based on an arbitrary threshold, these methods only select the DEGs that have large expression fold changes (<italic>FC</italic>) or significant <italic>P</italic>-values and treat each selected gene equally. Consequently, these methods achieve highly inconsistent results with small changes (e.g., 1.5 <italic>FC</italic> versus 2.0 <italic>FC</italic>) in thresholds.</p>
    <p id="Par43">To address these limitations, the second-generation methods called functional class scoring (FCS) were developed [<xref ref-type="bibr" rid="CR9">9</xref>]. FCS methods hypothesize that even though changes of individual genes are small in magnitude, their coordinated expression changes may have a greater impact in modulating a pathway/gene set [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. A well-known FCS method is the gene set enrichment analysis (GSEA) [<xref ref-type="bibr" rid="CR11">11</xref>]. GSEA first ranks genes by differential expression <italic>FC</italic>. Enrichment scores (<italic>ES</italic>s) are then calculated for predefined gene sets (pathways or functional gene sets) by considering how well the gene sets are enriched at the top or bottom of the ranked gene lists, which indicate their activation or repression, respectively. Therefore, FCS methods address the limitations of ORA methods.</p>
    <p id="Par44">Previous studies hypothesized that genes with different topological properties have different weights for the linked pathways [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. Because topology information of pathways was used, pathway topology-based (PT) approaches were demonstrated to perform better than the previous approaches and regarded as the third generation of PEA methods [<xref ref-type="bibr" rid="CR15">15</xref>]. The method CePa calculated the weight of a pathway node based on the network centralities [<xref ref-type="bibr" rid="CR13">13</xref>]. SPIA considered the influence of the neighboring nodes [<xref ref-type="bibr" rid="CR14">14</xref>]. TPEA integrated the global upstream/downstream positions and the degrees of all nodes in pathways [<xref ref-type="bibr" rid="CR12">12</xref>]. A significant drawback of PT methods is that they analyze pathways independently and neglect pathway crosstalk, a common and critical event in biology and disease development.</p>
    <p id="Par45">From the perspective of systems biology, genes may iteratively affect many other genes that exist in multiple pathways, causing pathway crosstalk that accounts for the phenotypes, such as crosstalk between ERK and WNT signaling in tumorigenesis [<xref ref-type="bibr" rid="CR16">16</xref>]. The latest generation of the PEA method is network topology-based (NT) approaches, which consider pathway crosstalk systematically in a network, such as latent pathway identification analysis (LPIA) [<xref ref-type="bibr" rid="CR17">17</xref>] and pathways based on network information (PathNet) [<xref ref-type="bibr" rid="CR18">18</xref>]. LPIA regarded each pathway as one node to construct an edge-weighted pathway network based on shared GO functions and DEGs. LPIA identified pathways by random walk algorithm according to network topology. Although LPIA considered pathway crosstalk, it ignores internal topology property within the pathway. PathNet integrated direct evidence (gene differential expression) and indirect evidence (neighbor gene differential expression), which considered gene interactions in both inter- and intra-pathway, as combined evidence for genes to assess their impacts on pathways. However, the gene interactions only depended on directed neighbors in the pathway network, and it ignored the impact of other genes.</p>
    <p id="Par46">As more biological knowledge was gained, protein-protein interaction (PPI) network and gene expression data were used to detect crosstalk between pathways [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Recently, by integrating pathway information, PPI network and gene expression data, Kelder et al. identified indirect associations between pathways in insulin-resistant mouse liver [<xref ref-type="bibr" rid="CR21">21</xref>]. However, in addition to PPI, transcription factor (TF) regulations also provide additional valuable information about molecular interactions. Additionally, these methods performed enrichment analysis mostly based on KEGG or GO, while numerous high-quality pathways or functional gene sets were also publicly available, such as Reactome [<xref ref-type="bibr" rid="CR22">22</xref>], PANTHER [<xref ref-type="bibr" rid="CR23">23</xref>], HumanCyc [<xref ref-type="bibr" rid="CR24">24</xref>], INOH [<xref ref-type="bibr" rid="CR25">25</xref>], NetPath [<xref ref-type="bibr" rid="CR26">26</xref>], PID [<xref ref-type="bibr" rid="CR27">27</xref>], and WikiPathways [<xref ref-type="bibr" rid="CR28">28</xref>]. Moreover, NT methods consume more time and more space because of their complexity. For example, LPIA may consume several hours for one test. Therefore, although commonly and widely used, current PEA methods have significant limitations, posing barriers to discovery.</p>
    <p id="Par47">In this study, we provided a new NT method for gene enrichment analysis called CTpathway: a crosstalk-based PEA method in a global pathway crosstalk map (GPCM) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). To obtain better speed, our method was optimized for running time to less than 1 min. Compared with existing methods, including DAVID, GSEA, TPEA, PathNet, and LPIA, CTpathway outperformed in terms of accuracy, robustness, and running time. In addition, CTpathway identified several important cancer pathways, which were not identified by other methods. Furthermore, CTpathway was useful even for data sets with fewer DEGs. By applying CTpathway for several cancer types of different stages (I, II, III, and IV), cancer target pathways were identified in early-stage tissues and blood samples. For breast cancer (BRCA) single-cell RNA-seq (scRNA-seq) data, CTpathway could identify the cell type-related pathways. We also developed an online web tool (<ext-link ext-link-type="uri" xlink:href="http://www.jianglab.cn/CTpathway/">http://www.jianglab.cn/CTpathway/</ext-link>) and the stand-alone program (<ext-link ext-link-type="uri" xlink:href="https://github.com/Bioccjw/CTpathway">https://github.com/Bioccjw/CTpathway</ext-link>) [<xref ref-type="bibr" rid="CR29">29</xref>], which allows users to simply upload the gene symbols or entrez gene IDs with log<sub>2</sub><italic>FC</italic> or <italic>P</italic>-values to identify risk pathways in a specific condition (e.g., disease) by performing the CTpathway method.<fig id="Fig1"><label>Fig. 1</label><caption><p>The workflow diagram for CTpathway. <bold>a</bold> GPCM and crosstalk effect matrix construction. GPCM was constructed by integrating pathway, TF regulation, and PPI information. Then, we evaluated the crosstalk effects in GPCM by applying the multi-RWR algorithm to calculate a crosstalk effect matrix <italic>C</italic>. <bold>b</bold> Gene differential expression (<italic>DE</italic>) score calculation. We integrated <italic>FC</italic> and <italic>P</italic>-value to calculate <italic>DE</italic> scores. Next, risk score (<italic>RS</italic>) for each gene and pathway score (<italic>PS</italic>) for each pathway were calculated to identify the significant risk pathways. <bold>c</bold> Visualization of significant pathways by bar graph, bubble plot, and enrichment map</p></caption><graphic xlink:href="13073_2022_1119_Fig1_HTML" id="MO1"/></fig></p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>Pathway data</title>
      <p id="Par48">We collected eight knowledgebases of human pathways including KEGG [<xref ref-type="bibr" rid="CR1">1</xref>], PANTHER [<xref ref-type="bibr" rid="CR23">23</xref>], Reactome [<xref ref-type="bibr" rid="CR22">22</xref>], HumanCyc [<xref ref-type="bibr" rid="CR24">24</xref>], INOH [<xref ref-type="bibr" rid="CR25">25</xref>], NetPath [<xref ref-type="bibr" rid="CR26">26</xref>], PID [<xref ref-type="bibr" rid="CR27">27</xref>], and WikiPathways [<xref ref-type="bibr" rid="CR28">28</xref>]. The interactions of gene and gene products in pathways of Reactome, HumanCyc, INOH, NetPath, PID, and WikiPathways were obtained from Pathway Commons version 10 [<xref ref-type="bibr" rid="CR30">30</xref>]. Because the information of KEGG and PANTHER in Pathway Commons was not updated, we extracted the interactions in KEGG and PANTHER in March 2019. For KEGG pathways, we downloaded KGML files of 299 pathways and extracted interaction information by iSubpathwayMiner R package [<xref ref-type="bibr" rid="CR31">31</xref>]. For PANTHER pathways, we downloaded BioPAX files of 138 pathways, and NetPathminer R package [<xref ref-type="bibr" rid="CR32">32</xref>] was used to extract interaction information. For the other six sources of pathways, we used gene interactions in Pathway Commons. In total, we obtained 375,256 interactions, including 11,556 genes from 2563 pathways involved in eight pathway databases (details in Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of data source information in GPCM</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Source of interactions</th><th>#Pathways</th><th>#Genes</th><th>#Interactions</th></tr></thead><tbody><tr><td>KEGG</td><td>299</td><td>5686</td><td>60,576</td></tr><tr><td>HumanCyc</td><td>238</td><td>1658</td><td>20,746</td></tr><tr><td>INOH</td><td>153</td><td>939</td><td>19,374</td></tr><tr><td>NetPath</td><td>27</td><td>1195</td><td>3727</td></tr><tr><td>PANTHER</td><td>129</td><td>2149</td><td>26,810</td></tr><tr><td>PID</td><td>212</td><td>2589</td><td>21,210</td></tr><tr><td>Reactome</td><td>1491</td><td>9990</td><td>266,500</td></tr><tr><td>WikiPathways</td><td>14</td><td>70</td><td>97</td></tr><tr><td>PPI</td><td>-</td><td>11,054</td><td>79,262</td></tr><tr><td>TRANSFAC</td><td>-</td><td>1947</td><td>4657</td></tr><tr><td>Total</td><td>2563</td><td>15,292</td><td>442,439</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec4">
      <title>TF-gene regulation data</title>
      <p id="Par49">We obtained experimentally validated TF-gene regulations from the TRANSFAC Professional database (release: February 2014) [<xref ref-type="bibr" rid="CR33">33</xref>]. TF-gene regulations, of which at least one node belongs to a pathway, were retained, including 491 TFs, 1614 genes, and 4657 pairs of regulation (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
    </sec>
    <sec id="Sec5">
      <title>PPI data</title>
      <p id="Par50">We obtained PPIs from 12 sources (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) collected by previous researchers [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. To obtain more reliable information, PPIs included in ≥2 sources were retained. Furthermore, we used interactions of which at least one of the interacting nodes belongs to a pathway. Finally, 79,262 PPIs, including 11,054 genes, were used for the next analysis (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
    </sec>
    <sec id="Sec6">
      <title>Constructing a global pathway crosstalk map (GPCM)</title>
      <p id="Par51">To consider pathway enrichment more systematically, we integrated three kinds of interactions including pathways, PPIs, and TF regulation for constructing a GPCM to simulate natural pathway crosstalk and adding biological knowledge. We used the union of pathway, PPI, and TF-gene information described above. For simplicity here, it was regarded as an undirected network. In total, the network includes 15,292 nodes and 442,439 edges (details in Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
    </sec>
    <sec id="Sec7">
      <title>Gold standard data sets</title>
      <p id="Par52">For comparing CTpathway accuracy with other PEA methods, we used gold standard data sets from the KEGGdzPathwaysGEO R package [<xref ref-type="bibr" rid="CR36">36</xref>]. It contained 24 data sets involving 12 diseases and 12 target pathways (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). One disease is corresponding to one target pathway. This data set was widely used as the gold standard for benchmarking in other methods [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. In addition, to test whether CTpathway could be applied in data sets with fewer DEGs, we analyzed 12 of 24 gold standard data sets with different numbers of DEGs (details in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).</p>
    </sec>
    <sec id="Sec8">
      <title>Cancer data sets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases</title>
      <p id="Par53">To evaluate reproducibility, we used both microarray data from the GEO database [<xref ref-type="bibr" rid="CR38">38</xref>] and RNA-seq data from the TCGA database [<xref ref-type="bibr" rid="CR39">39</xref>] for each of four cancer types (COAD, LIHC, LUAD, and OV). We downloaded eight gene expression data of four cancer types from the GEO database (GSE100179 [<xref ref-type="bibr" rid="CR40">40</xref>], GSE101685 [<xref ref-type="bibr" rid="CR41">41</xref>], GSE116959 [<xref ref-type="bibr" rid="CR42">42</xref>], GSE9891 [<xref ref-type="bibr" rid="CR43">43</xref>]) and TCGA database (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Each data set includes case (cancer) and control (normal) samples (details in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p>
      <p id="Par54">Furthermore, to test whether CTpathway could be applied in early-stage cancer samples, we analyzed ten data sets consisting of different cancer types available in TCGA or GEO (GSE20189; peripheral blood samples of LUAD patients [<xref ref-type="bibr" rid="CR44">44</xref>]) database. Each data set includes cancer samples of different cancer stages (I, II, III, and IV) and normal samples (details in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p>
      <p id="Par55">To test whether CTpathway could be applied in scRNA-seq data, we downloaded breast cancer (BRCA) scRNA-seq data from the GEO database (GSE118389 [<xref ref-type="bibr" rid="CR45">45</xref>]) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). The BRCA scRNA-seq data contains 1112 cells from six triple-negative breast cancer patients. Here, we used cell type annotation results according to the previous study [<xref ref-type="bibr" rid="CR45">45</xref>] including B cell, T cell, endothelial cell, epithelial cell, macrophage, and stromal cell. More details about the data sets are shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2.</p>
    </sec>
    <sec id="Sec9">
      <title>Differential expression</title>
      <p id="Par56">For the GEO microarray data set, we performed differential expression analysis by R package limma [<xref ref-type="bibr" rid="CR46">46</xref>] to obtain <italic>FC</italic> and <italic>P</italic>-value. For the TCGA RNA-seq data set, we used R package DESeq2 [<xref ref-type="bibr" rid="CR47">47</xref>] to obtain <italic>FC</italic> and <italic>P</italic>-value. OV data differential expression profile was from a previous study [<xref ref-type="bibr" rid="CR48">48</xref>]. For BRCA scRNA-seq data, we performed differential expression analysis between one cell type and the others using function "FindAllMarkers" in R package Seurat V3.2.2 [<xref ref-type="bibr" rid="CR49">49</xref>]. For some compared methods, which need a set of genes as input, such as DAVID, genes with <italic>FC</italic> &gt; 2 or <italic>FC</italic> &lt; 0.5 and <italic>P</italic>-value &lt; 0.05 were used for functional enrichment analysis. For LPIA, |log<sub>2</sub><italic>FC</italic>| value was used as differential expression score.</p>
    </sec>
    <sec id="Sec10">
      <title>Gene differential expression score</title>
      <p id="Par57">The <italic>FC</italic> and <italic>P</italic>-value are both important indexes to reflect the differential expression level of genes. Previous studies demonstrated that incorporating <italic>FC</italic> and <italic>P</italic>-value could provide significant improvement to meet the practical needs [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. We calculated a gene differential expression score to represent the impact of its disrupted expression on pathways. <italic>P</italic>-value ranges from 0 to 1. In order to make the <italic>FC</italic> value between 0 and 1, and keep genes with an <italic>FC</italic> value with <italic>n</italic> and 1/<italic>n</italic> having the same contribution weight, the gene differential expression score was calculated by Eq. (<xref rid="Equ1" ref-type="">1</xref>).<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$DE=\left\{\begin{array}{l}{\left(1-P\right)}^{\alpha}\times {\left[1-{(FC)}^{-\frac{1}{2}}\right]}^{\beta }, FC\geq 1\\ {}{\left(1-P\right)}^{\alpha}\times {\left[1-{(FC)}^{\frac{1}{2}}\right]}^{\beta },0\le FC&lt; 1\end{array}\right.$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfenced open="{"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>P</mml:mi></mml:mfenced></mml:mrow><mml:mi>α</mml:mi></mml:msup><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfenced close="]" open="["><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msup></mml:mfenced></mml:mrow><mml:mi>β</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>≥</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mrow/><mml:mrow/><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>P</mml:mi></mml:mfenced></mml:mrow><mml:mi>α</mml:mi></mml:msup><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mfenced close="]" open="["><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:msup></mml:mfenced></mml:mrow><mml:mi>β</mml:mi></mml:msup><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par58">When <italic>P</italic>-value (or <italic>FC</italic>) is available or not, <italic>α</italic> (or <italic>β</italic>) equals to 1 or 0. <italic>DE</italic> is the differential expression score, represented as a vector:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$DE=\left[\begin{array}{c}{DE}_1\\ {}{DE}_2\\ {}\vdots \\ {}{DE}_i\\ {}\vdots \\ {}{DE}_L\end{array}\right]$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mi>D</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfenced close="]" open="["><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi mathvariant="italic">DE</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mrow><mml:mi mathvariant="italic">DE</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mrow><mml:mi mathvariant="italic">DE</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mrow><mml:mi mathvariant="italic">DE</mml:mi></mml:mrow><mml:mi>L</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>where <italic>L</italic> is the intersection number of genes in the expression profile and genes in the GPCM.</p>
    </sec>
    <sec id="Sec11">
      <title>Risk score (RS)</title>
      <p id="Par59">Here in GPCM, for one gene, we calculated a risk score integrating all the nodes (genes) impact on this node (gene). The GPCM was defined as a simple undirected graph <italic>G</italic> = (<italic>V</italic>, <italic>E</italic>), where a <italic>v</italic> ∈ <italic>V</italic> represents a gene and a <italic>e</italic> ∈ <italic>E</italic> represents an edge. First, one gene in the expression file was taken as a seed (i.e., <italic>i</italic>), and given an initial weight score of 1. Then, a random walk with restart (RWR) algorithm [<xref ref-type="bibr" rid="CR52">52</xref>] was used to simulate the propagation process of crosstalk effect <italic>C</italic><sub><italic>i</italic></sub> from one to others.<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C}_i^t =r\times W\times{C}_i^{t-1} +\left(1-r\right)\times {N}_i$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:msubsup><mml:mi>C</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>×</mml:mo><mml:mi>W</mml:mi><mml:mo>×</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfenced close=")" open="("><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>r</mml:mi></mml:mfenced><mml:mo>×</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq1"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${C}_i^1= {N}_i$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:msubsup><mml:mi>C</mml:mi><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq1.gif"/></alternatives></inline-formula>, <italic>r</italic> is the restart coefficient, <italic>t</italic> is iteration times, <italic>W</italic> was a |<italic>N</italic>| × |<italic>N</italic>| column-normalized adjacent matrix of graph <italic>G</italic>, and <italic>N</italic><sub><italic>i</italic></sub> is a |<italic>N</italic>| × 1 vector with <italic>i</italic>th element equal to 1 and others all equal to 0. Next, with respect to all the genes in the expression file, we iterated over each gene as a seed. This process was called a multiple random walk with restart (multi-RWR) algorithm (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Here, we measured the magnitude of change between states <italic>t</italic> and <italic>t</italic>-1 as the sum of the absolute difference of the <italic>C</italic><sup><italic>t</italic></sup> and <italic>C</italic><sup><italic>t-</italic>1</sup>. The threshold was set as 10<sup>−10</sup> to control the iteration times. When it was less than 10<sup>−10</sup>, the iterative computation would stop. Finally, we obtained a crosstalk effect for all genes, named as the crosstalk effect matrix, represented as a matrix:<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$C={\left[\begin{array}{cccccc}{C}_{11}&amp; {C}_{12}&amp; \cdots &amp; {C}_{1j}&amp; \cdots &amp; {C}_{1N}\\ {}{C}_{21}&amp; {C}_{22}&amp; \cdots &amp; {C}_{2j}&amp; \cdots &amp; {C}_{2N}\\ {}\vdots &amp; \vdots &amp; \vdots \vdots \vdots &amp; \vdots &amp; \vdots \vdots \vdots &amp; \vdots \\ {}{C}_{i1}&amp; {C}_{i2}&amp; \cdots &amp; {C}_{ij}&amp; \cdots &amp; {C}_{iN}\\ {}\vdots &amp; \vdots &amp; \vdots \vdots \vdots &amp; \vdots &amp; \vdots \vdots \vdots &amp; \vdots \\ {}{C}_{L1}&amp; {C}_{L2}&amp; \cdots &amp; {C}_{Lj}&amp; \cdots &amp; {C}_{LN}\end{array}\right]}^T$$\end{document}</tex-math><mml:math id="M10" display="block"><mml:mrow><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mn>11</mml:mn></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mn>12</mml:mn></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mi>C</mml:mi><mml:mn>21</mml:mn></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mn>22</mml:mn></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">iN</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd><mml:mtd><mml:mrow><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo><mml:mo>⋮</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>⋮</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:mrow/><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>L</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">Lj</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd><mml:mo>⋯</mml:mo></mml:mtd><mml:mtd><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">LN</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>where <italic>C</italic><sub><italic>ij</italic></sub> represents the crosstalk effect of gene <italic>j</italic> impacted by gene <italic>i</italic>. Last, we integrated <italic>C</italic> matrix and <italic>DE</italic> vector to calculate the risk score (<italic>RS</italic>) as follows:<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$RS=C\times DE$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mi>R</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mo>×</mml:mo><mml:mi>D</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula><fig id="Fig2"><label>Fig. 2</label><caption><p>CTpathway algorithm diagram including Multi-RWR. First, gene 1 in the expression profile was taken out as a seed and RWR was used to obtain the crosstalk effect <italic>C</italic><sub>1</sub> on all nodes in the network. Next, another gene <italic>i</italic> was chosen to repeat this progress and obtained <italic>C</italic><sub><italic>i</italic></sub>. Finally, we obtained the crosstalk effect matrix <italic>C</italic> after all genes in the profile were taken out as a seed. We also calculated the differential expression (<italic>DE</italic>) score by integrating <italic>FC</italic> and <italic>P</italic>-value. Using both crosstalk and differential expression, we obtained the risk score <inline-formula id="IEq2"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${RS}_{j_i}$$\end{document}</tex-math><mml:math id="M14"><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:msub><mml:mi>j</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq2.gif"/></alternatives></inline-formula> of gene <italic>j</italic> impacted by gene <italic>i</italic>. We integrated the risk score of gene <italic>j</italic> impacted by all genes as gene <italic>j</italic> risk score <italic>RS</italic><sub><italic>j</italic></sub>. Finally, we obtained a pathway risk score (<italic>PS</italic>) by averaging all gene risk scores in a pathway and calculated the significance level by permutation</p></caption><graphic xlink:href="13073_2022_1119_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par60">For example, we calculated an <italic>RS</italic> of gene <italic>j</italic> impacted by gene <italic>i</italic> as follows:<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${RS}_{j_i}={C}_{ij}\times {DE}_i$$\end{document}</tex-math><mml:math id="M16" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:msub><mml:mi>j</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">DE</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq3"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${RS}_{j_i}$$\end{document}</tex-math><mml:math id="M18"><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:msub><mml:mi>j</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq3.gif"/></alternatives></inline-formula> represents the risk score of gene <italic>j</italic> impacted by gene <italic>i</italic> and <italic>DE</italic><sub><italic>i</italic></sub> represents the differential expression score of gene <italic>i</italic>.</p>
      <p id="Par61">For gene <italic>j</italic>, we integrated scores impacted by all genes as the final gene risk score (<italic>RS</italic><sub><italic>j</italic></sub>) as follows:<disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${RS}_j =\sum\limits_{i=1}^L{RS}_{j_i}$$\end{document}</tex-math><mml:math id="M20" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:munderover><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:msub><mml:mi>j</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msub></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ7.gif" position="anchor"/></alternatives></disp-formula>where <italic>L</italic> is the intersection number of genes in the expression profile and genes in the GPCM.</p>
    </sec>
    <sec id="Sec12">
      <title>The pathway enrichment score</title>
      <p id="Par62">We obtained <italic>RS</italic> of each gene in GPCM. For a pathway <italic>k</italic>, we calculated a pathway enrichment score <italic>PS</italic><sub><italic>k</italic></sub> as the average of <italic>RS</italic> values for the genes in pathway <italic>k</italic>. The formula is as follows:<disp-formula id="Equ8"><label>8</label><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PS}_k =\frac{1}{n}\sum\limits_{j=1}^n{RS}_j$$\end{document}</tex-math><mml:math id="M22" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">PS</mml:mi></mml:mrow><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:msub><mml:mrow><mml:mi mathvariant="italic">RS</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ8.gif" position="anchor"/></alternatives></disp-formula>where <italic>n</italic> represents the number of genes in pathway <italic>k</italic>.</p>
    </sec>
    <sec id="Sec13">
      <title>Identification of significant pathways</title>
      <p id="Par63">We performed the permutation analysis to estimate the significance of the pathway. First, we shuffled genes in the differential expression profile. Then, we calculated the pathway enrichment score for each pathway. The background distribution was generated after performing <italic>h</italic> permutations. For a pathway, the empirical <italic>P</italic>-value was defined as the proportion of random pathway enrichment scores (<italic>PS</italic><sub><italic>random</italic></sub>) larger than the real pathway enrichment score (<italic>PS</italic>): <italic>P</italic>-value = <inline-formula id="IEq4"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${}^{\left({N}_{PS_{random}&gt; PS}\right)\!}\left/ \!{}_{h}\right.$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:msup><mml:mrow/><mml:mrow><mml:mfenced close=")" open="("><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi mathvariant="italic">random</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mspace width="-0.166667em"/></mml:mrow></mml:msup><mml:mfenced open="/"><mml:mspace width="-0.166667em"/><mml:msub><mml:mrow/><mml:mi>h</mml:mi></mml:msub></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq4.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq5"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{PS_{random}&gt; PS}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi mathvariant="italic">random</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mi>P</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq5.gif"/></alternatives></inline-formula> was the number of random pathways that had larger scores than the real pathway. Here, <italic>h</italic> was 1000. However, because of the limited number of permutations, it often produces a <italic>P</italic>-value of 0. To solve this problem, we estimated the exact <italic>P</italic>-value by using the generalized Pareto distribution (GPD) [<xref ref-type="bibr" rid="CR53">53</xref>]. Because many pathways were involved in this analysis, it was necessary to perform multiple hypothesis testing methods to control the proportion of false positives. We applied the false discovery rate (<italic>FDR</italic>) to account for false positives [<xref ref-type="bibr" rid="CR54">54</xref>]. The pathways with <italic>FDR</italic> &lt; 0.01 were considered as significant pathways. In addition, CTpathway automatically clusters significant pathways into non-redundant groups. Pairwise similarities between any two significant pathways are computed based on a <italic>Jaccard</italic> similarity coefficient. According to user’s input cutoff of <italic>Jaccard</italic> similarity coefficient, a pathway similarity network is constructed. A default coefficient of 0.3 was set up in this study, which could be customized by the users using our web server. The Markov Cluster (MCL) algorithm [<xref ref-type="bibr" rid="CR55">55</xref>] was employed to perform clustering process. CTpathway chooses the most significant (lowest <italic>FDR</italic>) pathway within each cluster to represent the cluster. To obtain a better visualization, CTpathway shows the top 20 non-redundant pathways or clusters with low <italic>FDR</italic>, if there are more than 20 clusters or pathways. For each cluster, the top 10 pathways with lower <italic>FDR</italic> are shown in the enrichment map if there are more than 10 pathways which are within one cluster.</p>
    </sec>
    <sec id="Sec14">
      <title>Rank difference (DR) and time difference (DT) values</title>
      <p id="Par64"><italic>DR</italic> value was calculated to represent the rank difference (before and after optimization) of the target pathway as follows:<disp-formula id="Equ9"><label>9</label><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$DR=\sum\limits_{m=1}^M\frac{\left|{R}_{b_m}-{R}_{a_m}\right|}{K}/M$$\end{document}</tex-math><mml:math id="M28" display="block"><mml:mrow><mml:mi>D</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mfrac><mml:mfenced close="|" open="|"><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>b</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:mfenced><mml:mi>K</mml:mi></mml:mfrac><mml:mo stretchy="false">/</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ9.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq6"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}_{b_m}$$\end{document}</tex-math><mml:math id="M30"><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>b</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq6.gif"/></alternatives></inline-formula> represents the rank of the target pathway in data set <italic>m</italic> before optimization and <inline-formula id="IEq7"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}_{a_m}$$\end{document}</tex-math><mml:math id="M32"><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq7.gif"/></alternatives></inline-formula> represents the rank of the target pathway in data set <italic>m</italic> after optimization. <italic>M</italic> is the number of data sets. <italic>K</italic> is the number of total KEGG pathways. Here, <italic>M</italic> is 24 and <italic>K</italic> is 299.</p>
      <p id="Par65"><italic>DT</italic> value was calculated to represent the running time difference (before and after optimization) as follows:<disp-formula id="Equ10"><label>10</label><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$DT=\sum\limits_{m=1}^M\frac{T_{b_m}-{T}_{a_m}}{T_{b_m}}/M$$\end{document}</tex-math><mml:math id="M34" display="block"><mml:mrow><mml:mi>D</mml:mi><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:msub><mml:mi>b</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:msub><mml:mi>b</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:mfrac><mml:mo stretchy="false">/</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ10.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq8"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{b_m}$$\end{document}</tex-math><mml:math id="M36"><mml:msub><mml:mi>T</mml:mi><mml:msub><mml:mi>b</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq8.gif"/></alternatives></inline-formula> represents the running time in data set <italic>m</italic> before the optimization, and <inline-formula id="IEq9"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{a_m}$$\end{document}</tex-math><mml:math id="M38"><mml:msub><mml:mi>T</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq9.gif"/></alternatives></inline-formula> represents the running time in data set <italic>m</italic> after the optimization.</p>
    </sec>
    <sec id="Sec15">
      <title>Rank ratio (RR) value</title>
      <p id="Par66"><italic>RR</italic> value was used as the criteria to compare the accuracy of different tools. Each data set <italic>m</italic> had an <italic>RR</italic> value for its target pathway, represented as <italic>RR</italic><sub><italic>m</italic></sub>, which was the rank ratio of the target pathway in data set <italic>m</italic>, and calculated as follows:<disp-formula id="Equ11"><label>11</label><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${RR}_m=\frac{R_{a_m}}{M}$$\end{document}</tex-math><mml:math id="M40" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">RR</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub><mml:mi>M</mml:mi></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ11.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq10"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${R}_{a_m}$$\end{document}</tex-math><mml:math id="M42"><mml:msub><mml:mi>R</mml:mi><mml:msub><mml:mi>a</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:msub></mml:math><inline-graphic xlink:href="13073_2022_1119_Article_IEq10.gif"/></alternatives></inline-formula> and <italic>M</italic> were described as above. To make it comparable between different methods, we used KEGG pathways as candidate pathways.</p>
    </sec>
    <sec id="Sec16">
      <title>Stability (S) value</title>
      <p id="Par67"><italic>S</italic> value was used as the criteria to compare the stability or reproducibility of different tools. First, for eight data sets of four cancer types, each of which has microarray data and RNA-seq data, we identified risk pathways by using different methods. For each cancer type, we compared shared significant pathways identified from microarray data and RNA-Seq data. Because compared methods just identified few pathways or no pathways when using routine <italic>FDR</italic> or adjusted <italic>P</italic>-value as a cutoff, pathways with <italic>P</italic>-value &lt; 0.05 were identified as significant pathways for all methods here. <italic>S</italic> value was calculated as follows:<disp-formula id="Equ12"><label>12</label><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$S=\sum\limits_{d=1}^D\frac{J_d}{D}$$\end{document}</tex-math><mml:math id="M44" display="block"><mml:mrow><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>D</mml:mi></mml:munderover><mml:mfrac><mml:msub><mml:mi>J</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mi>D</mml:mi></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="13073_2022_1119_Article_Equ12.gif" position="anchor"/></alternatives></disp-formula>where <italic>J</italic><sub><italic>d</italic></sub> represents the <italic>Jaccard</italic> similarity coefficient of different data sets of cancer type <italic>d</italic> and <italic>D</italic> represents the number of all cancer types. In this study, <italic>D</italic> is 4.</p>
    </sec>
    <sec id="Sec17">
      <title>Statistics analysis</title>
      <p id="Par68">Differential expression analysis was performed by R package limma for the GEO data set and R package DESeq2 for the TCGA data set. <italic>P</italic>-value &lt; 0.05 was considered to be statistically significant for DEGs. For CTpathway, permutation analysis was performed to estimate the significance of the pathway; <italic>FDR</italic> &lt; 0.01 was considered as significant. For GSEA, <italic>FDR</italic> &lt; 0.01 was considered as significant. For other compared methods, <italic>P</italic>-value &lt; 0.05 was considered as significant because few pathways or no pathways were identified when using routine <italic>FDR</italic> or adjusted <italic>P</italic>-value as a cutoff.</p>
    </sec>
    <sec id="Sec18">
      <title>Benchmarking</title>
      <p id="Par69">In this study, CTpathway was compared with five widely used tools, including DAVID, GSEA, TPEA, LPIA, and PathNet, in terms of accuracy, reproducibility, and running time. For accuracy, we compared <italic>RR</italic> values for each method using 24 gold standard data sets (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). For reproducibility, we compared the <italic>S</italic> value calculated for four cancer types (COAD, LIHC, LUAD, and OV) based on different sources (TCGA RNA-seq data and GEO microarray data) of eight gene expression data (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). For the running time, we used simulated data sets of 500, 1000, 5000, 10,000, and 20,000 genes. Because most of these methods only focused on the pathways defined in KEGG, we used KEGG pathways for comparative analysis when benchmarking.</p>
    </sec>
    <sec id="Sec19">
      <title>Hardware platform</title>
      <p id="Par70">All benchmarks were performed on a computer with 2*Intel Xeon E5-2609 V4 Processor, 2*64G DDR4 RDIMM, 8 DIMM slots, 1*128G SSD 2.5, 1*2TB SATA 3.5, and 2*1080Ti.</p>
    </sec>
    <sec id="Sec20">
      <title>Code availability</title>
      <p id="Par71">CTpathway web server is available at <ext-link ext-link-type="uri" xlink:href="http://www.jianglab.cn/CTpathway/">http://www.jianglab.cn/CTpathway/</ext-link>. The CTpathway stand-alone program is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/Bioccjw/CTpathway">https://github.com/Bioccjw/CTpathway</ext-link> [<xref ref-type="bibr" rid="CR29">29</xref>]. Other custom codes used in this study are available from the corresponding authors upon reasonable request.</p>
    </sec>
  </sec>
  <sec id="Sec21">
    <title>Results</title>
    <sec id="Sec22">
      <title>Global pathway crosstalk map (GPCM) and its properties</title>
      <p id="Par72">By integrating three kinds of interactions including the regulation of TFs to genes from TRANSFAC [<xref ref-type="bibr" rid="CR33">33</xref>], the PPIs from multiple sources in previous studies [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], and the pathways from eight databases (KEGG [<xref ref-type="bibr" rid="CR1">1</xref>], Reactome [<xref ref-type="bibr" rid="CR22">22</xref>], PANTHER [<xref ref-type="bibr" rid="CR23">23</xref>], HumanCyc [<xref ref-type="bibr" rid="CR49">49</xref>], INOH [<xref ref-type="bibr" rid="CR25">25</xref>], NetPath [<xref ref-type="bibr" rid="CR26">26</xref>], PID [<xref ref-type="bibr" rid="CR27">27</xref>], and WikiPathways [<xref ref-type="bibr" rid="CR28">28</xref>]), we constructed a GPCM that included 15,292 nodes and 442,439 edges (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a and Table <xref rid="Tab1" ref-type="table">1</xref>). Next, we investigated the topological properties of the GPCM. The degree distribution approximately displayed a power law distribution (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b), indicating the network satisfied scale-free topology, a general concept for biological networks. There are some well-known signaling and transcription factor genes with a high degree in the GPCM, such as <italic>EGFR</italic>, <italic>AKT</italic>, <italic>MYC</italic>, and <italic>p53</italic> (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). The gene with the highest degree in the network is <italic>GNB1</italic>, a subunit of G proteins, which are modulators or transducers in various transmembrane signaling pathways and included in 234 pathways. In addition, we determined that ~75% (<italic>n</italic> &gt; 8800) of the genes participate in more than one pathway (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). Density distribution of pathways showed a positively skewed distribution, which suggested that only a few pathways include a higher number of genes (Fig. <xref rid="Fig3" ref-type="fig">3</xref>d). Most of the genes participate in multiple pathways, which suggest that crosstalk exists. Pathway crosstalk was represented by integrating molecular interactions and pathways into a GPCM.<fig id="Fig3"><label>Fig. 3</label><caption><p>Overview and characteristics of the GPCM. <bold>a</bold> GPCM. Different colors represent different kinds of nodes. Gray dots represent genes from at least two kinds of interactions (pathway, PPI, or TF regulation). <bold>b</bold> The degree distribution of GPCM. <bold>c</bold> The cumulative distribution of the number of genes in pathways. The pie chart shows the proportion of genes in one pathway and in more than one pathway. <bold>d</bold> The density distribution of the number of pathways</p></caption><graphic xlink:href="13073_2022_1119_Fig3_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec23">
      <title>Crosstalk effect evaluation and pathway identification</title>
      <p id="Par73">Pathways are usually affected by each other in the process of performing functions due to crosstalk [<xref ref-type="bibr" rid="CR16">16</xref>]. We evaluated the crosstalk effects in GPCM by applying a multi-RWR algorithm to calculate a crosstalk effect matrix, <italic>C</italic>, which exploits the complete network topology (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) (details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section). Then, we integrated <italic>FC</italic> and <italic>P</italic>-value as gene differential expression score (<italic>DE</italic>) to reflect the disturbed level of gene expression (details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section). Next, we integrated the <italic>C</italic> matrix and differential expression score (<italic>DE</italic>) to calculate a risk score (<italic>RS</italic>) as the impact of the gene on the pathways (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section). For gene <italic>i</italic>, <italic>RS</italic><sub><italic>i</italic></sub> reflects the risk score of the node <italic>i</italic> in the context of GPCM. We further tested the relationship between <italic>RS</italic> and |log<sub>2</sub><italic>FC|</italic> based on a lung adenocarcinoma (LUAD) data set (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) available in the GEO database (GSE116959 [<xref ref-type="bibr" rid="CR42">42</xref>]). Despite a higher positive correlation (Pearson correlation coefficient <italic>R</italic> ≈ 0.84) (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1), we determined several known lung cancer-associated genes with high <italic>RS</italic> and low |log<sub>2</sub><italic>FC|</italic> (Table <xref rid="Tab2" ref-type="table">2</xref> and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1), such as <italic>TRIM</italic>28, <italic>APP</italic>, <italic>ESR</italic>1, <italic>MYC</italic>, and <italic>EGFR</italic> [<xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR59">59</xref>]. However, these genes would be overlooked by most of the existing PEA methods because they only consider significant DEGs or high |log<sub>2</sub><italic>FC|</italic> genes.<table-wrap id="Tab2"><label>Table 2</label><caption><p>The representative 10 genes with high <italic>RS</italic> and low |log<sub>2</sub><italic>FC</italic>| value in LUAD (GSE116959)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene symbol</th><th>EntreZ ID</th><th>|log<sub>2</sub><italic>FC</italic>| value</th><th><italic>DE</italic> value</th><th><italic>RS</italic></th><th>Reference (PMID)</th></tr></thead><tbody><tr><td><italic>TRIM</italic>28</td><td>10155</td><td>0.3854</td><td>0.1186</td><td>2.3781</td><td>33091876</td></tr><tr><td><italic>APP</italic></td><td>351</td><td>0.3965</td><td>0.1244</td><td>1.4413</td><td>25502341</td></tr><tr><td><italic>SP</italic>1</td><td>6667</td><td>0.2215</td><td>0.0690</td><td>1.2031</td><td>22158040</td></tr><tr><td><italic>GRB</italic>2</td><td>2885</td><td>0.3315</td><td>0.1051</td><td>1.0874</td><td>26693065, 27449805</td></tr><tr><td><italic>PPP1CA</italic></td><td>5499</td><td>0.2363</td><td>0.0686</td><td>0.8904</td><td>29285244</td></tr><tr><td><italic>POT</italic>1</td><td>25913</td><td>0.3106</td><td>0.0485</td><td>0.7578</td><td>19285750</td></tr><tr><td><italic>ESR</italic>1</td><td>2099</td><td>0.0278</td><td>0.0013</td><td>0.7493</td><td>11929836, 16033821</td></tr><tr><td><italic>MYC</italic></td><td>4609</td><td>0.3150</td><td>0.0947</td><td>0.7396</td><td>22941188, 28089889</td></tr><tr><td><italic>CDK</italic>2</td><td>1017</td><td>0.3184</td><td>0.1035</td><td>0.7185</td><td>25301183</td></tr><tr><td><italic>EGFR</italic></td><td>1956</td><td>0.0841</td><td>0.0091</td><td>0.6921</td><td>8391303, 10767376</td></tr></tbody></table></table-wrap></p>
      <p id="Par74">Additionally, we questioned whether <italic>RS</italic> would reflect gene risk better than |log<sub>2</sub><italic>FC|</italic>. First, we downloaded cancer causal genes (CCGs) from the Cancer Gene Census (CGC) [<xref ref-type="bibr" rid="CR60">60</xref>]. We obtained CCGs for four cancer types (COAD, LIHC, LUAD, and OV) separately (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Tables S2 and S5). Then, we obtained two gene expression data sets for each of these cancer types from two independent sources (TCGA and GEO, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) and performed differential expression analysis. For each data set, we ranked genes according to their |log<sub>2</sub><italic>FC|</italic> and <italic>RS</italic> from high to low, separately. Next, we evaluated if CCGs were located in the top of the rank list by the GSEA method [<xref ref-type="bibr" rid="CR11">11</xref>]. The results showed that CCGs were significantly located in the top of the <italic>RS</italic> rank list for all 8 data sets at a significance level of <italic>FDR</italic> &lt;0.1, whereas all |log<sub>2</sub><italic>FC|</italic>-based <italic>FDR</italic>s were &gt;0.1 (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2 and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S6). Here, the CCGs with low |log<sub>2</sub><italic>FC</italic>| achieved high <italic>RS</italic> through crosstalk with those high |log<sub>2</sub><italic>FC</italic>| genes in GPCM. These results indicated that <italic>RS</italic> was a better index for identifying casual genes, and thus, pathways enriched with high <italic>RS</italic> genes are likely to have important roles. Moreover, the proportion of risk genes in the top 100 of the <italic>RS</italic> rank list with |log<sub>2</sub><italic>FC</italic>| &lt;1 varied from 17 to 60% for eight data sets. This set of high-risk genes would have been overlooked if only considering the DEG analysis (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S3).</p>
      <p id="Par75">Finally, we calculated a pathway enrichment score, <italic>PS</italic>, by integrating the <italic>RS</italic> of all nodes in the pathway. We took the average of the <italic>RS</italic> values in a pathway <italic>k</italic> as <italic>PS</italic><sub><italic>k</italic></sub>. By permutation, we identified the significant dysregulated pathways (details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section).</p>
    </sec>
    <sec id="Sec24">
      <title>Parameter optimization and improved performance compared to existing tools</title>
      <p id="Par76">We tested the performance of different <italic>r</italic> values based on 24 gold standard data sets involving 12 human diseases (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). In general, there was a slight variance on the performance with different <italic>r</italic> values. In this study, <italic>r</italic> was set as 0.7 because CTpathway had the best performance (Fig. <xref rid="Fig4" ref-type="fig">4</xref>a). In addition, we only kept <italic>ε</italic> digits and set values smaller than 10<sup>−<italic>ε</italic></sup> to 0 for the <italic>C</italic> matrix to improve running speed. Here, the threshold <italic>ε</italic> was set to 3, which consequently completes the job in less than 50 s (86.3% reduction of running time) without compromising the quality of the results (rank difference = 0.018) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b).<fig id="Fig4"><label>Fig. 4</label><caption><p>CTpathway outperforms other methods. <bold>a</bold> Box plot of target pathway <italic>RR</italic> values for different <italic>r</italic> values. <bold>b</bold> The impact of different <italic>ε</italic> values (<italic>x</italic>-axis) on <italic>DT</italic> (left <italic>y</italic>-axis) and <italic>DR</italic> (right <italic>y</italic>-axis) values. <bold>c</bold>–<bold>f</bold> Comparative analysis of the performance of different methods in terms of accuracy (<italic>RR</italic> and ROC curve), reproducibility, and running time, respectively. “*” represents two-sided <italic>t</italic>-test <italic>P</italic>-value &lt; 0.05; “**” represents <italic>P</italic>-value &lt; 0.01; “***” represents <italic>P</italic>-value &lt; 0.001; ns represents not significant</p></caption><graphic xlink:href="13073_2022_1119_Fig4_HTML" id="MO4"/></fig></p>
      <p id="Par77">To illustrate the effectiveness of the proposed method in identifying dysregulated pathways, our results were compared with five widely used tools, including DAVID (first-generation method) [<xref ref-type="bibr" rid="CR4">4</xref>], GSEA (second-generation method) [<xref ref-type="bibr" rid="CR11">11</xref>], TPEA (third-generation method) [<xref ref-type="bibr" rid="CR12">12</xref>], LPIA (fourth-generation method) [<xref ref-type="bibr" rid="CR17">17</xref>], and PathNet (fourth-generation method) [<xref ref-type="bibr" rid="CR18">18</xref>]. Because most of these methods only focused on the pathways defined in KEGG, we used KEGG pathways for this comparative analysis (details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section).</p>
      <p id="Par78">First, accuracy was compared by using 24 gold standard data sets (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) [<xref ref-type="bibr" rid="CR36">36</xref>]. We compared the <italic>RR</italic> values of the target pathways obtained from different tools (Fig. <xref rid="Fig4" ref-type="fig">4</xref>c). CTpathway had the significantly lower <italic>RR</italic> values than other methods (no significant change compared to PathNet), indicating that our method was more accurate. Moreover, the comparisons of ROC curves and AUC values also indicated CTpathway had the best performance (Fig. <xref rid="Fig4" ref-type="fig">4</xref>d).</p>
      <p id="Par79">Reproducibility is also very important. Currently, most of the PEA methods are not sufficiently reproducible because of only using DEGs and insufficiently using pathway topology and molecular interaction information. To evaluate the stability of the methods, we calculated the <italic>S</italic> value (details in the “<xref rid="Sec2" ref-type="sec">Methods</xref>” section) for four cancer types (COAD, LIHC, LUAD, and OV) based on different sources (TCGA RNA-seq data and GEO microarray data) of eight gene expression data sets (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). The results showed that CTpathway achieved the highest <italic>S</italic> value in all comparisons (Fig. <xref rid="Fig4" ref-type="fig">4</xref>e). Therefore, our data showed that CTpathway outperformed other tools in generating reproducible results.</p>
      <p id="Par80">Next, we compared the running time of CTpathway with other methods such as GSEA, TPEA, PathNet, and LPIA. Because DAVID was used on the web server, the running time of which might be interfered by the internet connection speed, it was excluded. We used simulated data sets of 500, 1000, 5000, 10,000, and 20,000 genes. Our results demonstrated that CTpathway outperformed other methods, particularly as gene number increased. As the number of genes rose, increased running time was observed in TPEA, PathNet, and GSEA, whereas no change in running time occurred in CTpathway and LPIA (Fig. <xref rid="Fig4" ref-type="fig">4</xref>f). However, LPIA running time was days compared to CTpathway, which took less than 50 s to analyze one set of data regardless of gene number, demonstrating that our method was independent of gene set size. Taken together, our data show that CTpathway has greater accuracy, higher reproducibility, and less running time compared to other methods.</p>
    </sec>
    <sec id="Sec25">
      <title>CTpathway identifies risk pathways in cancers</title>
      <p id="Par81">To demonstrate the utility of CTpathway, we firstly applied it to eight gene expression data sets of four tumor types (COAD, LIHC, LUAD, and OV; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). In eight pathway databases, we identified significant pathways for the four tumor types at a significance level of <italic>FDR</italic> &lt; 0.01 (Fig. <xref rid="Fig5" ref-type="fig">5</xref>a and b, and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S7-S14). The number of identified pathways in different pathway databases differed. In general, the number of identified pathways in the Reactome database was relatively higher because of more candidate pathways. The total number of significant pathways for the eight gene expression data varied from approximately 300 to 500, accounting for 11.7~19.5% of all candidate pathways (Fig. <xref rid="Fig5" ref-type="fig">5</xref>b). Some well-known cancer pathways were significant in more than one cancer type (Fig. <xref rid="Fig5" ref-type="fig">5</xref>a and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S7-S14). For example, the “AP-1 transcription factor network” was identified as a significant pathway across four cancer types over all eight data sets. The AP-1 transcription factor is involved in a wide range of biological processes, such as cell growth, proliferation, differentiation, apoptosis, migration, and invasion [<xref ref-type="bibr" rid="CR61">61</xref>–<xref ref-type="bibr" rid="CR64">64</xref>]. “FOXM1 transcription factor network,” “Degradation of the extracellular matrix,” and “Activation of matrix metalloproteinases” appeared in seven data sets. Many previous studies have demonstrated that these pathways are altered in multiple cancer types, indicating their pan-cancer regulation potential [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR70">70</xref>]. We also identified pathways unique to a single cancer. For example, transport-related pathways (“Transferrin endocytosis and recycling” and “Passive transport by Aquaporins”) were reproducibly identified in COAD in both the GSE100179 [<xref ref-type="bibr" rid="CR40">40</xref>] and TCGA patient cohort and not in other cancers. Many metabolism-linked pathways (“Pyruvate metabolism,” “Glycerolipid metabolism,” “Glycogen degradation II,” “Acetate conversion to acetyl-CoA,” and “Caffeine metabolism”) were specifically identified in LIHC patient cohorts in TCGA and GEO (GSE101685 [<xref ref-type="bibr" rid="CR41">41</xref>]). Previous reports demonstrated that a large number of metabolic processes are dysregulated in LIHC to fuel tumorigenesis [<xref ref-type="bibr" rid="CR71">71</xref>], suggesting our method accurately identifies dysregulated pathways in cancer. Several transcription or signal transduction-related pathways (“RUNX1 regulates transcription of genes involved in differentiation of HSCs,” “NOTCH1 Intracellular Domain Regulates Transcription,” “Constitutive Signaling by NOTCH1 PEST Domain Mutants”) were shared by GEO (GSE116959 [<xref ref-type="bibr" rid="CR42">42</xref>]) and TCGA LUAD patient cohorts, but not in other cancers. In OV, immune and EMT/migration/invasion-related pathways were observed, such as “TCR,” “IL3,” “E-cadherin signaling in the nascent adherens junction,” “RUNX2 regulates genes involved in cell migration,” “Adherens junction,” and “Stabilization and expansion of the E-cadherin adherens junction” pathways. Importantly, these pathways have been reported to impact cell and/or organ functions and/or tumorigenesis [<xref ref-type="bibr" rid="CR72">72</xref>–<xref ref-type="bibr" rid="CR82">82</xref>]. Collectively, our results show that CTpathway accurately identifies well-known cancer risk pathways.<fig id="Fig5"><label>Fig. 5</label><caption><p>CTpathway accurately identifies well-known cancer risk pathways. <bold>a</bold> The comparison of identified pathways in four cancers for eight data sets. Gray color represents identified pathways across multiple cancer types (AC). Other colors represent cancer type-specific identified pathways. GT represents both GEO and TCGA data sets; TS and GS represent TCGA specific and GEO specific, respectively. For cancer type-specific identified pathways, the proportion of pathways for different data sets is shown as pie charts. <bold>b</bold> Heatmap of pathways identified for eight cancer data sets by CTpathway in eight pathway databases. The number of candidate pathways for each database is indicated in parentheses. <bold>c</bold> The bar graph shows the top 10 KEGG pathways</p></caption><graphic xlink:href="13073_2022_1119_Fig5_HTML" id="MO5"/></fig></p>
      <p id="Par82">Most of the pathways are previously verified known risk pathways for the individual cancer types, indicating CTpathway is a highly reliable tool for prioritizing the risk pathways. Taking GEO LUAD and OV data sets as examples, all the top 10 pathways for LUAD and nine of the top 10 pathways for OV have been reported (Fig. <xref rid="Fig5" ref-type="fig">5</xref>c, Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S15-S19). We also compared risk pathways identified by different methods. We determined that all of the top 10 risk pathways for both LUAD and OV in CTpathway were also identified by other methods (Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S15-S19). However, four of the top 10 pathways for LUAD or OV were identified by only one or two existing methods (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S15-S19), such as “Tuberculosis,” “Focal adhesion,” and “ECM-receptor interaction,” which play critical roles in cancer pathogenesis or progression [<xref ref-type="bibr" rid="CR83">83</xref>–<xref ref-type="bibr" rid="CR85">85</xref>]. Moreover, we determined the pathways only identified by CTpathway for OV (Table <xref rid="Tab4" ref-type="table">4</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S17-S19), and most of these pathways were cancer-related such as “MAPK signaling pathway” [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], “Wnt signaling pathway” [<xref ref-type="bibr" rid="CR88">88</xref>], and “Hippo signaling pathway” [<xref ref-type="bibr" rid="CR89">89</xref>]. We also determined that these pathways had a lower proportion of DEG (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S4). For example, CTpathway identified “MAPK signaling pathway” (Table <xref rid="Tab4" ref-type="table">4</xref>), which has important roles in the development and survival of many cancer types including ovarian cancer [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Also, there is a crosstalk between “MAPK signaling pathway” and “ECM-receptor interaction” (Fig. <xref rid="Fig6" ref-type="fig">6</xref>a), which had been demonstrated to aid in EMT/migration/invasion process [<xref ref-type="bibr" rid="CR90">90</xref>–<xref ref-type="bibr" rid="CR92">92</xref>]. Five of six methods including CTpathway identified “ECM-receptor interaction” as a risk pathway (Table <xref rid="Tab3" ref-type="table">3</xref>); however, all of the other compared methods were unable to determine “MAPK signaling pathway” as a risk pathway in EMT in OV. Furthermore, we determined that there was a lower proportion of DEGs in the “MAPK signaling pathway” (1.4% [4/295]) than that in the “ECM-receptor interaction” pathway (18.5% [15/81]); thus, most methods will identify “ECM-receptor interaction” instead of “MAPK signaling pathway.” Because the “MAPK signaling pathway” has crosstalk with “ECM-receptor interaction,” with most DEGs (14/15) in the “ECM-receptor interaction” having a direct connection with the “MAPK signaling pathway,” most “MAPK signaling pathway” genes have high <italic>RS</italic> (Fig. <xref rid="Fig6" ref-type="fig">6</xref>a, b). Therefore, only our method identified “MAPK signaling pathway” as a risk pathway. Moreover, we determined that, in the top 100 of the <italic>RS</italic> rank list, there are 36 EMT genes [<xref ref-type="bibr" rid="CR93">93</xref>], of which seven have low |log<sub>2</sub><italic>FC</italic>| (|log<sub>2</sub><italic>FC</italic>| &lt; 1) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>c and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S20). These genes were easily overlooked by other methods that only considered DEGs as risk genes. Taken together, CTpathway could identify cancer risk pathways that were identified by existing methods, and importantly, also significant pathways and risk genes that were overlooked by other methods.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Top 10 significant pathways identified by CTpathway based on the GSE116959 LUAD data set</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Pathway name</th><th>#Node</th><th><italic>PS</italic></th><th><italic>P</italic>-value</th><th><italic>FDR</italic></th><th><italic>D</italic><sup>a</sup></th><th><italic>G</italic><sup>a</sup></th><th><italic>G</italic><sup>a</sup></th><th><italic>P</italic><sup>a</sup></th><th><italic>L</italic><sup>a</sup></th></tr></thead><tbody><tr><td>hsa05200</td><td>Pathways in cancer</td><td>454</td><td>0.187</td><td>1.37×10<sup>−8</sup></td><td>2.52×10<sup>−6</sup></td><td>√</td><td/><td>√</td><td>√</td><td/></tr><tr><td>hsa05152</td><td>Tuberculosis</td><td>175</td><td>0.164</td><td>1.69×10<sup>−8</sup></td><td>2.52×10<sup>−6</sup></td><td/><td>√</td><td/><td/><td>√</td></tr><tr><td>hsa05140</td><td>Leishmaniasis</td><td>72</td><td>0.233</td><td>2.58×10<sup>−8</sup></td><td>2.57×10<sup>−6</sup></td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td></tr><tr><td>hsa05133</td><td>Pertussis</td><td>52</td><td>0.239</td><td>1.03×10<sup>−7</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td>√</td><td>√</td><td/><td>√</td></tr><tr><td>hsa04110</td><td>Cell cycle</td><td>124</td><td>0.237</td><td>6.88×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td>√</td><td>√</td><td>√</td><td/></tr><tr><td>hsa04510</td><td>Focal adhesion</td><td>199</td><td>0.201</td><td>4.49×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td/><td/><td/><td/></tr><tr><td>hsa05166</td><td>Human T-cell leukemia virus 1 infection</td><td>233</td><td>0.196</td><td>9.77×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td/><td/><td/><td>√</td></tr><tr><td>hsa04512</td><td>Ascorbate and ECM-receptor interaction</td><td>81</td><td>0.181</td><td>8.56×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td/><td/><td/><td>√</td></tr><tr><td>hsa04610</td><td>Complement and coagulation cascades</td><td>55</td><td>0.171</td><td>8.71×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td/><td>√</td><td>√</td><td>√</td></tr><tr><td>hsa05150</td><td><italic>Staphylococcus aureus</italic> infection</td><td>39</td><td>0.171</td><td>8.20×10<sup>−8</sup></td><td>3.09×10<sup>−6</sup></td><td>√</td><td>√</td><td/><td/><td>√</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>D</italic> DAVID, <italic>G</italic> GSEA, <italic>T</italic> TPEA, <italic>P</italic> PathNet, <italic>L</italic> LPIA</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Top 10 significant pathways only identified by CTpathway based on the GSE9891 OV data set</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Pathway name</th><th>#Node</th><th><italic>PS</italic></th><th><italic>P</italic>-value</th><th><italic>FDR</italic></th><th>DEG proportion</th></tr></thead><tbody><tr><td>hsa04072</td><td>Phospholipase D signaling pathway</td><td>118</td><td>0.096</td><td>1.44×10<sup>−7</sup></td><td>1.65×10<sup>−6</sup></td><td>0.025</td></tr><tr><td>hsa04010</td><td>MAPK signaling pathway</td><td>295</td><td>0.085</td><td>3.14×10<sup>−7</sup></td><td>2.47×10<sup>−6</sup></td><td>0.014</td></tr><tr><td>hsa04550</td><td>Signaling pathways regulating pluripotency of stem cells</td><td>109</td><td>0.109</td><td>7.30×10<sup>−7</sup></td><td>5.08×10<sup>−6</sup></td><td>0.037</td></tr><tr><td>hsa04310</td><td>Wnt signaling pathway</td><td>144</td><td>0.096</td><td>1.45×10<sup>−6</sup></td><td>8.85×10<sup>−6</sup></td><td>0.028</td></tr><tr><td>hsa05202</td><td>Transcriptional misregulation in cancer</td><td>19</td><td>0.140</td><td>1.85×10<sup>−6</sup></td><td>1.11×10<sup>−5</sup></td><td>0.053</td></tr><tr><td>hsa05212</td><td>Pancreatic cancer</td><td>75</td><td>0.126</td><td>2.60×10<sup>−6</sup></td><td>1.49×10<sup>−5</sup></td><td>0</td></tr><tr><td>hsa01521</td><td>EGFR tyrosine kinase inhibitor resistance</td><td>79</td><td>0.113</td><td>4.28×10<sup>−6</sup></td><td>2.35×10<sup>−5</sup></td><td>0.038</td></tr><tr><td>hsa05225</td><td>Hepatocellular carcinoma</td><td>168</td><td>0.093</td><td>9.76×10<sup>−6</sup></td><td>5.12×10<sup>−5</sup></td><td>0.006</td></tr><tr><td>hsa04390</td><td>Hippo signaling pathway</td><td>153</td><td>0.090</td><td>1.15×10<sup>−5</sup></td><td>5.85×10<sup>−5</sup></td><td>0.032</td></tr><tr><td>hsa05224</td><td>Breast cancer</td><td>145</td><td>0.096</td><td>3.42×10<sup>−5</sup></td><td>1.49×10<sup>−4</sup></td><td>0.014</td></tr></tbody></table></table-wrap><fig id="Fig6"><label>Fig. 6</label><caption><p>“MAPK signaling pathway” aid in EMT in OV. <bold>a</bold> Crosstalk between “MAPK signaling pathway” and “ECM-receptor interaction.” The red nodes represent DEGs and the gray nodes are non-DEGs. Fourteen of 15 DEGs in the “ECM-receptor interaction” pathway have a direct connection with the “MAPK signaling pathway.” <bold>b</bold> The risks of genes in the “MAPK signaling pathway.” Risks were measured by <italic>FC</italic>, <italic>FDR</italic>, DEG, and <italic>RS. </italic><bold>c</bold> The bar graph shows EMT genes in the top 100 of the <italic>RS</italic> rank list in OV</p></caption><graphic xlink:href="13073_2022_1119_Fig6_HTML" id="MO6"/></fig></p>
    </sec>
    <sec id="Sec26">
      <title>CTpathway identifies risk pathways in data sets with fewer DEGs</title>
      <p id="Par83">Because of its algorithmic properties, we postulated that CTpathway would be useful for data sets with a small number of DEGs. To test this, we screened DEGs for 24 gold standard data sets at a level of |log<sub>2</sub><italic>FC</italic>| &gt; 1 and <italic>FDR</italic> &lt; 0.1 and selected 12 representative gold standard data sets with different numbers of DEGs ranging from 0 to 1702 (Fig. <xref rid="Fig7" ref-type="fig">7</xref>a and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3). We compared KEGG pathways identified by CTpathway with those by other five methods (DAVID, GSEA, TPEA, PathNe, and LPIA) at a significance level of <italic>FDR</italic>-corrected <italic>P</italic>-value &lt; 0.05 (Fig. <xref rid="Fig7" ref-type="fig">7</xref>a). The number of significant pathways identified by CTpathway was independent from the number of DEGs. For data sets with fewer DEGs, CTpathway could identify more pathways than all other methods. However, other methods, including DAVID, GSEA, and TPEA, showed a greater dependency on the number of DEGs. They could only identify a small number of significant pathways for data sets with fewer DEGs (e.g., GSE6956C [<xref ref-type="bibr" rid="CR94">94</xref>] and GSE1297 [<xref ref-type="bibr" rid="CR95">95</xref>]). Furthermore, CTpathway could identify target pathways for most (9/12) of the data sets, whereas other methods had a lower rate of identification and overlooked them, especially for data sets with fewer DEGs. We also compared significant pathways at a level of nominal <italic>P</italic>-value &lt; 0.05 (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S5), and CTpathway could identify target pathways independent on the number of DEGs. These results demonstrated that CTpathway outperformed other methods for target pathway identification, particularly when there are a small number of DEGs.<fig id="Fig7"><label>Fig. 7</label><caption><p>CTpathway identifies significant pathways in data sets with few DEGs and early-stage cancer patients. <bold>a</bold> The comparison of identified pathways for data sets with a different number of DEGs in six methods. The bar graph shows the number of DEGs for 12 representative data sets. The heatmap shows the number of significant pathways at the significance level of <italic>FDR</italic> &lt; 0.05, identified by different methods for data sets with a different number of DEGs, divided by the number of all candidate pathways. The target pathways are marked as green stars. <bold>b</bold> The heatmap of enrichment results (<italic>P</italic>-value) for the target pathways of 10 early-stage cancer types using different methods. <bold>c</bold>, <bold>d</bold> Enrichment results (<italic>P</italic>-value, <italic>y</italic>-axis) for the target pathways of TCGA COAD data sets of tissue samples (<bold>c</bold>) and LUAD blood samples (<bold>d</bold>) of different stages using different methods. The dashed line represents a cutoff (<italic>P</italic>-value = 0.05)</p></caption><graphic xlink:href="13073_2022_1119_Fig7_HTML" id="MO7"/></fig></p>
    </sec>
    <sec id="Sec27">
      <title>CTpathway identifies risk pathways in early-stage cancer</title>
      <p id="Par84">Cancer diagnosis relies on detecting symptoms followed by histology/pathology evaluation. Identification of altered pathways indicative of pre-malignancy or early-stage cancer is critical for disease prevention and earlier treatment, leading to improved outcomes for patients. Early-stage cancers usually show smaller changes at the molecular level than late-stage cancers. We tested whether CTpathway could identify risk pathways for early-stage disease in cancer patients. First, samples of 10 cancer types that included stages I, II, III, and IV were obtained from TCGA. We selected the KEGG annotated ten pathways specific for the ten cancer types (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). For each cancer type of each stage, pathway enrichment analysis was performed by CTpathway and other methods. The <italic>P</italic>-values of target pathways were compared by different methods. The results showed that CTpathway performed better than the other methods for tissue samples (Fig. <xref rid="Fig7" ref-type="fig">7</xref>b, c and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S6). In general, the CTpathway <italic>P</italic>-values of target pathways were smaller than those of other methods. Even in the early-stage (stage I) patients, 9/10 target pathways of cancer types could be identified by CTpathway at a significance level of <italic>P</italic>-value &lt; 0.05, whereas all but one other method could either not identify any or only identified one target pathway in early-stage patients for one cancer type (Fig. <xref rid="Fig7" ref-type="fig">7</xref>b). In addition, we also evaluated blood samples, which are easier to obtain from patients as compared to tissue samples. CTpathway was applied to the data sets of the blood samples (GSE20189 [<xref ref-type="bibr" rid="CR44">44</xref>]) from LUAD patients of different stages (I, II, III, and IV), and it identified the target pathway in the early stage as well as performed better than the other methods across all cancer stages (Fig. <xref rid="Fig7" ref-type="fig">7</xref>d). These results demonstrate that CTpathway may be useful for early disease diagnosis.</p>
    </sec>
    <sec id="Sec28">
      <title>CTpathway identifies cell type-related pathways in scRNA-seq data</title>
      <p id="Par85">Due to characteristics of scRNA-seq data such as drop-out events and low library sizes, the number of DEGs for a subgroup or cell type is typically low. Because CTpathway is not limited by DEG number, we postulated it could be utilized in scRNA-seq data. To test this, we obtained BRCA scRNA-seq data (GSE118389 [<xref ref-type="bibr" rid="CR45">45</xref>]). Cell types were annotated (B cell, T cell, macrophage, endothelial cell, epithelial cell, and stromal cell) according to the reported study [<xref ref-type="bibr" rid="CR45">45</xref>]. Differential expression analysis was performed between one cell type and the others by Seurat V3.2.2 [<xref ref-type="bibr" rid="CR49">49</xref>]. Then, CTpathway was applied to each cell type. The pathway enrichment results showed that CTpathway could identify known cell type-related pathways in each cell type (Fig. <xref rid="Fig8" ref-type="fig">8</xref>). For example, “B cell receptor signaling pathway” was significant in B cell (<italic>FDR</italic> = 1.48×10<sup>−6</sup>) [<xref ref-type="bibr" rid="CR96">96</xref>]; “Neurophilin interactions with VEGF and VEGFR” was significant in endothelial cell (<italic>FDR</italic> = 5.06×10<sup>−6</sup>) [<xref ref-type="bibr" rid="CR97">97</xref>]; “Toll-like receptor signaling pathway” was significant in macrophage (<italic>FDR</italic> = 6.47×10<sup>−6</sup>) [<xref ref-type="bibr" rid="CR98">98</xref>]; “ECM-receptor interaction” was significant in stromal cell (<italic>FDR</italic> = 1.61×10<sup>−6</sup>) [<xref ref-type="bibr" rid="CR99">99</xref>]; “TCR” was significant in T cell (<italic>FDR</italic> = 6.21×10<sup>−7</sup>) [<xref ref-type="bibr" rid="CR100">100</xref>]. Compared to other methods, CTpathway showed the lowest <italic>RR</italic> value for the “B cell receptor signaling pathway” in B cell (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S7). These results demonstrated that CTpathway could effectively identify cell type-related functions or pathways in scRNA-seq data.<fig id="Fig8"><label>Fig. 8</label><caption><p>CTpathway identifies cell type-related pathways in BRCA scRNA-seq data. The heatmap of enrichment results (<italic>PS</italic> value) of pathways in each cell type determined by CTpathway</p></caption><graphic xlink:href="13073_2022_1119_Fig8_HTML" id="MO8"/></fig></p>
    </sec>
    <sec id="Sec29">
      <title>Reduction of pathway redundancy</title>
      <p id="Par86">Redundancy is a frequently neglected problem for most PEA methods. Pathways sharing genes lead to functional similarities. As a result, it is difficult to extract representative pathways from redundant information [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. CTpathway automatically clusters enriched pathways into non-redundant groups. Briefly, we constructed a similarity network after obtaining significant pathways based on a particular cutoff of the <italic>Jaccard</italic> similarity coefficient for shared genes among all significant pathway pairs. MCL clustering algorithm [<xref ref-type="bibr" rid="CR55">55</xref>] was employed to absorb most redundancies into representative clusters. Each cluster was renamed as the name of the most significant pathway in this cluster. Taking TCGA COAD stage I patient samples as an example (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S8), we determined some clusters with two or more pathways, and our method enables robust identification of the remaining single node clusters, indicating that these risk pathways reveal potentially targetable pathways, as they have the least amount of crosstalk with other pathways. Therefore, CTpathway is designed to obtain non-redundant pathway information to better interpret pathway enrichment results, and this is dictated according to the needs of the user who input a cutoff of the <italic>Jaccard</italic> similarity coefficient on the web server.</p>
    </sec>
    <sec id="Sec30">
      <title>Web-based implementation of CTpathway</title>
      <p id="Par87">We provided an online web tool for users to perform pathway enrichment analysis with CTpathway (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9). Users can input data including gene (gene symbol or entrez ID), both log<sub>2</sub><italic>FC</italic> and <italic>P</italic>-value or either. By selecting several parameters, input Email address, and clicking the “run” button (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9a and b, more details in the Web Manual page), CTpathway returns enrichment results shown in the table in the result page of the web server. The results are also visualized by a bar graph, a bubble plot, and an enrichment map (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S9c-e). Users can choose any or all results according to their needs. In the web server, results only take a few minutes.</p>
    </sec>
  </sec>
  <sec id="Sec31">
    <title>Discussion</title>
    <p id="Par88">PEA is a useful method for exploring gene set function. However, most existing methods did not consider pathway crosstalk and priori knowledge. In this study, we designed and provided to the research community CTpathway, a crosstalk-based PEA method through a global pathway crosstalk map (GPCM) by using multiple sources of pathways and priori knowledge in human.</p>
    <p id="Par89">First, we collected TF-gene regulation, PPI, and gene-gene interaction and constructed a GPCM. The topological property analysis showed that the degree distribution approximately displayed a power law distribution, which was similar to most biological networks. Then, we integrated <italic>FC</italic> and <italic>P</italic>-value for each gene from differential expression analysis as gene differential expression score (<italic>DE</italic>). Next, we obtained a crosstalk effect matrix by the multi-RWR algorithm and calculated a final risk score (<italic>RS</italic>) by integrating the <italic>DE</italic> and crosstalk effects. By enrichment analysis of the CGC genes, we demonstrated that <italic>RS</italic> was a better index for identifying risk genes, and identified important genes with a high <italic>RS</italic> and low |log<sub>2</sub><italic>FC</italic>| that were overlooked by other methods that relied on |log<sub>2</sub><italic>FC</italic>|. Finally, we calculated a pathway enrichment score by averaging <italic>RS</italic> for genes in the pathway and identified significantly dysregulated pathways by permutation. Our optimization process reduced ~86.3% of the original running time. Furthermore, the performance of CTpathway is significantly better compared with existing methods in terms of accuracy (<italic>RR</italic> and AUC value), reproducibility, and running time. In addition, by applying CTpathway to cancer patient samples, we determined that CTpathway could identify critical pathways, which were not identified by other methods. For the data sets with a small number of DEGs, CTpathway was also useful and outperformed the other methods. Notably, CTpathway outperformed other methods in identifying target pathways in early-stage cancer tissues and blood samples. For scRNA-seq data, which can have small DEG numbers, CTpathway could effectively identify cell type-related pathways. Our results demonstrate that CTpathway could be applied in disease analysis, and especially for data sets with fewer DEGs, early cancer diagnosis, which may lead to starting treatment earlier, and scRNA-seq data. We also developed an online web tool to allow users to easily and freely perform PEA with CTpathway.</p>
    <p id="Par90">This study provides a new useful PEA method, CTpathway, for over 2500 pathways in eight pathway databases, and showed that CTpathway performed better than other widely used methods. We evaluated CTpathway performance using the commonly used standard data sets. However, these data sets are limiting because there are only 24 target pathways for 24 diseases, indicating a need in the field for more gold standard data sets for the evaluation of pathway enrichment analysis methods. If the data sets contained additional known risk pathways for diseases, the methods could be evaluated more precisely using the precision-recall curve and AUPRC. In addition, CTpathway still has limitations related to reproducibility, which is consistent with PEA methods overall. For example, when different data sets belonging to the same disease serve as input, the results may differ. While differences in samples and sample handling and processing between different labs contribute to reproducibility challenges, CTpathway was more reproducible than the other methods, showing ~35% overlap between different data sets tested.</p>
    <p id="Par91">Of note, the NT methods are highly dependent on the information of interactions, such as TF-gene regulations, PPIs, and gene-gene interactions, and thus, incomplete information will limit the development of these methods. In this study, TF-gene regulations come from the TRANSFAC database. Recently, several other resources of TF-gene regulation have been provided [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Adding more TF-gene regulations might lead to a potential improvement of CTpathway. Notably, CTpathway could be extended to predict non-coding RNA (ncRNA) functions by adding ncRNA regulations or interactions into GPCM. Moreover, CTpathway only focuses on <italic>Homo sapiens</italic> in this version. Through constructing GPCM for other species, CTpathway could be used to identify risk pathways of other species. Although future studies will be needed to investigate these areas, CTpathway provides a new publicly available method that should result in new discoveries in multiple fields of biology and disease research.</p>
  </sec>
  <sec id="Sec32">
    <title>Conclusions</title>
    <p id="Par92">This study presents a novel pathway crosstalk-based method, CTpathway, for performing pathway enrichment analysis. CTpathway outperformed existing methods on accuracy, reproducibility, and speed. CTpathway exclusively identified critical pathways in several cancer types. Furthermore, CTpathway was useful even for data sets with few differentially expressed genes and could identify target pathways in early-stage cancer patient samples, which could lead to earlier treatment, and identify cell type-related pathways for scRNA-seq data. Finally, we provide an interactive and easy-to-use web server so users can conveniently perform pathway enrichment analysis and discover disease-risk pathways.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec33">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="13073_2022_1119_MOESM1_ESM.xlsx">
            <caption>
              <p><bold>Additional file 1: Table S1.</bold> Information of protein-protein (PPI) included in this study. <bold>Table S2.</bold> Summary of data sets analyzed in this study. <bold>Table S3.</bold> Summary of 12 gold standard data sets. <bold>Table S4.</bold> The degree of genes in the GPCM. <bold>Table S5.</bold> List of CGC genes of four cancer types. <bold>Table S6.</bold> GSEA enrichment results of <italic>RS</italic> or |log<sub>2</sub><italic>FC</italic>| for CGC genes. <bold>Tables S7-S14.</bold> Significant (<italic>FDR</italic> &lt; 0.01) pathways identified by CTpathway for GEO COAD, TCGA COAD, GEO LIHC, TCGA LIHC, GEO LUAD, TCGA LUAD, GEO OV, TCGA OV. <bold>Tables S15-S18.</bold> Comparative results show significant KEGG pathways identified by CTpathway with other methods from GEO LUAD, TCGA LUAD, GEO OV, TCGA OV data. <bold>Table S19.</bold> Significant (<italic>FDR</italic> &lt; 0.01) KEGG pathways for GEO OV data only identified by CTpathway. <bold>Table S20.</bold> EMT genes in the top 100 of <italic>RS</italic> rank list.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="13073_2022_1119_MOESM2_ESM.pdf">
            <caption>
              <p><bold>Additional file 2: Figure S1.</bold> Crosstalk effect consideration detects genes known to be associated with LUAD. <bold>Figure S2.</bold> CGC genes are in top of the <italic>RS</italic> rank list, but not top of the |log<sub>2</sub><italic>FC</italic>| rank list. <bold>Figure S3.</bold> The proportion of risk genes, overlooked by other methods. <bold>Figure S4.</bold> Comparison of DEG proportions between pathways specifically identified by CTpathway and non-specific pathways. <bold>Figure S5.</bold> Significant pathways in data sets with a small number of DEGs, identified by CTpathway. <bold>Figure S6.</bold> Comparison of enrichment result (<italic>P</italic>-value) of target pathways for TCGA cancer stages (I, II, III and IV), obtained by different methods. <bold>Figure S7.</bold> Enrichment result (<italic>RR</italic> value) comparison of target pathways for B cell by different methods. <bold>Figure S8.</bold> An enrichment map constructed from early-stage COAD data set. <bold>Figure S9.</bold> The publicly available CTpathway web tool.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>BRCA</term>
        <def>
          <p id="Par27">Breast cancer</p>
        </def>
      </def-item>
      <def-item>
        <term>C</term>
        <def>
          <p id="Par5">Crosstalk effect matrix</p>
        </def>
      </def-item>
      <def-item>
        <term>COAD</term>
        <def>
          <p id="Par6">Colon adenocarcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>DE</term>
        <def>
          <p id="Par7">Differential expression score</p>
        </def>
      </def-item>
      <def-item>
        <term>DEGs</term>
        <def>
          <p id="Par8">Differentially expressed genes</p>
        </def>
      </def-item>
      <def-item>
        <term>DR</term>
        <def>
          <p id="Par11">Rank difference</p>
        </def>
      </def-item>
      <def-item>
        <term>DT</term>
        <def>
          <p id="Par12">Time difference</p>
        </def>
      </def-item>
      <def-item>
        <term>ESs</term>
        <def>
          <p id="Par31">Enrichment scores</p>
        </def>
      </def-item>
      <def-item>
        <term>FC</term>
        <def>
          <p id="Par13">Fold change</p>
        </def>
      </def-item>
      <def-item>
        <term>FCS</term>
        <def>
          <p id="Par14">Functional class scoring</p>
        </def>
      </def-item>
      <def-item>
        <term>FDR</term>
        <def>
          <p id="Par38">False discovery rate</p>
        </def>
      </def-item>
      <def-item>
        <term>GEO</term>
        <def>
          <p id="Par35">Gene Expression Omnibus</p>
        </def>
      </def-item>
      <def-item>
        <term>GO</term>
        <def>
          <p id="Par30">Gene Ontology</p>
        </def>
      </def-item>
      <def-item>
        <term>GPCM</term>
        <def>
          <p id="Par15">Global pathway crosstalk map</p>
        </def>
      </def-item>
      <def-item>
        <term>GPD</term>
        <def>
          <p id="Par37">Generalized Pareto distribution</p>
        </def>
      </def-item>
      <def-item>
        <term>GSEA</term>
        <def>
          <p id="Par28">Gene set enrichment analysis</p>
        </def>
      </def-item>
      <def-item>
        <term>KEGG</term>
        <def>
          <p id="Par29">Kyoto Encyclopedia of Genes and Genomes</p>
        </def>
      </def-item>
      <def-item>
        <term>LIHC</term>
        <def>
          <p id="Par16">LIVER hepatocellular carcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>LPIA</term>
        <def>
          <p id="Par32">Latent pathway identification analysis</p>
        </def>
      </def-item>
      <def-item>
        <term>LUAD</term>
        <def>
          <p id="Par17">Lung adenocarcinoma</p>
        </def>
      </def-item>
      <def-item>
        <term>MCL</term>
        <def>
          <p id="Par40">Markov Cluster</p>
        </def>
      </def-item>
      <def-item>
        <term>multi-RWR</term>
        <def>
          <p id="Par18">Multiple random walk with restart</p>
        </def>
      </def-item>
      <def-item>
        <term>NT</term>
        <def>
          <p id="Par19">Network topology-based</p>
        </def>
      </def-item>
      <def-item>
        <term>ORA</term>
        <def>
          <p id="Par20">Over-representation analysis</p>
        </def>
      </def-item>
      <def-item>
        <term>PathNet</term>
        <def>
          <p id="Par33">Pathways based on network information</p>
        </def>
      </def-item>
      <def-item>
        <term>PEA</term>
        <def>
          <p id="Par21">Pathway enrichment analysis</p>
        </def>
      </def-item>
      <def-item>
        <term>PPI</term>
        <def>
          <p id="Par9">Protein-protein interaction</p>
        </def>
      </def-item>
      <def-item>
        <term>PS</term>
        <def>
          <p id="Par22">Pathway enrichment score</p>
        </def>
      </def-item>
      <def-item>
        <term>PT</term>
        <def>
          <p id="Par23">Pathway topology-based</p>
        </def>
      </def-item>
      <def-item>
        <term>RR</term>
        <def>
          <p id="Par10">Rank ratio</p>
        </def>
      </def-item>
      <def-item>
        <term>RS</term>
        <def>
          <p id="Par24">Risk score</p>
        </def>
      </def-item>
      <def-item>
        <term>S</term>
        <def>
          <p id="Par39">Stability</p>
        </def>
      </def-item>
      <def-item>
        <term>scRNA-seq</term>
        <def>
          <p id="Par34">Single-cell RNA-seq</p>
        </def>
      </def-item>
      <def-item>
        <term>TCGA</term>
        <def>
          <p id="Par36">The Cancer Genome Atlas</p>
        </def>
      </def-item>
      <def-item>
        <term>TF</term>
        <def>
          <p id="Par26">Transcription factor</p>
        </def>
      </def-item>
      <def-item>
        <term>THCA</term>
        <def>
          <p id="Par25">Thyroid cancer</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher’s Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Haizhou Liu, Mengqin Yuan and Ramkrishna Mitra contributed equally to this work.</p>
    </fn>
  </fn-group>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>WJ designed the study; HZL, MQY, and RM carried out the data acquisition and analysis and drafted the manuscript; XZ, ML, and WYL performed the statistical analysis; SHZ, YEH, and FH provided scientific advice and contributed to result interpretations; RM and CME provided scientific advice and contributed to result interpretations and the writing of the manuscript. The authors read and approved the final manuscript. HZL, MQY, and RM contributed equally to this work.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China [61872183, 62172213] to WJ. This work was also supported by the National Institute of Health/National Cancer Institute grants R01CA177786 (CME), R01CA236853 (CME), and P30CA056036 that supports the Sidney Kimmel Cancer Center at Thomas Jefferson University, and the Herbert A. Rosenthal Endowed Chair fund (CME) and the Steinfort Research Fund.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The CTpathway web server is available from <ext-link ext-link-type="uri" xlink:href="http://www.jianglab.cn/CTpathway/">http://www.jianglab.cn/CTpathway/</ext-link>. The CTpathway stand-alone program is available from <ext-link ext-link-type="uri" xlink:href="https://github.com/Bioccjw/CTpathway">https://github.com/Bioccjw/CTpathway</ext-link> [<xref ref-type="bibr" rid="CR29">29</xref>]. All data used could be obtained from public sources (details in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). Twenty-four gold standard data sets were obtained from the KEGGdzPathwaysGEO R package [<xref ref-type="bibr" rid="CR36">36</xref>]. Eight gene expression data of four cancer types (COAD, LIHC, LUAD, and OV) were downloaded from the GEO database [<xref ref-type="bibr" rid="CR38">38</xref>] (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) under accession numbers GSE100179 [<xref ref-type="bibr" rid="CR40">40</xref>], GSE101685 [<xref ref-type="bibr" rid="CR41">41</xref>], GSE116959 [<xref ref-type="bibr" rid="CR42">42</xref>], and GSE9891 [<xref ref-type="bibr" rid="CR43">43</xref>] and the TCGA database [<xref ref-type="bibr" rid="CR39">39</xref>] (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>). Cancer data of different stages were downloaded from the TCGA (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>) and GEO (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>, under accession number GSE20189 [<xref ref-type="bibr" rid="CR44">44</xref>]) databases. BRCA scRNA-seq data were obtained from the GEO database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) under accession number GSE118389 [<xref ref-type="bibr" rid="CR45">45</xref>]. Cancer causal genes were obtained from the Cancer Gene Census (CGC) [<xref ref-type="bibr" rid="CR60">60</xref>] (<ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/census/">https://cancer.sanger.ac.uk/census/</ext-link>).</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par93">Not applicable.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par94">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par95">Dr. Eischen discloses research funding from AbbVie unrelated to this manuscript. The remaining authors declare they have no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>
        <source>Nucleic Acids Res</source>
        <year>2017</year>
        <volume>45</volume>
        <fpage>D353</fpage>
        <lpage>D361</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
        <?supplied-pmid 27899662?>
        <pub-id pub-id-type="pmid">27899662</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Gene Ontology C</collab>
        </person-group>
        <article-title>Gene Ontology Consortium: going forward</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>D1049</fpage>
        <lpage>D1056</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1179</pub-id>
        <pub-id pub-id-type="pmid">25428369</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <mixed-citation publication-type="other">Wang X, Yin TS, Boyi LI, Jiang XL, Sun H, Dou YG, et al. Progress in gene functional enrichment analysis. Sci Sin Vitae. 2016;46:363-73.</mixed-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dennis</surname>
            <given-names>G</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Hosack</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Lane</surname>
            <given-names>HC</given-names>
          </name>
          <name>
            <surname>Lempicki</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>DAVID: database for annotation, visualization, and integrated discovery</article-title>
        <source>Genome Biol</source>
        <year>2003</year>
        <volume>4</volume>
        <fpage>P3</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2003-4-5-p3</pub-id>
        <?supplied-pmid 12734009?>
        <pub-id pub-id-type="pmid">12734009</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jaehnig</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs</article-title>
        <source>Nucleic Acids Res</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>W199</fpage>
        <lpage>W205</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id>
        <?supplied-pmid 31114916?>
        <pub-id pub-id-type="pmid">31114916</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bindea</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mlecnik</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hackl</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Charoentong</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tosolini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kirilovsky</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fridman</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>Pages</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Trajanoski</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Galon</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>1091</fpage>
        <lpage>1093</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id>
        <?supplied-pmid 19237447?>
        <pub-id pub-id-type="pmid">19237447</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pache</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Khodabakhshi</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Tanaseichuk</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Benner</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chanda</surname>
            <given-names>SK</given-names>
          </name>
        </person-group>
        <article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title>
        <source>Nat Commun</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>1523</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id>
        <?supplied-pmid 30944313?>
        <pub-id pub-id-type="pmid">30944313</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beissbarth</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Speed</surname>
            <given-names>TP</given-names>
          </name>
        </person-group>
        <article-title>GOstat: find statistically overrepresented Gene Ontologies within a group of genes</article-title>
        <source>Bioinformatics</source>
        <year>2004</year>
        <volume>20</volume>
        <fpage>1464</fpage>
        <lpage>1465</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bth088</pub-id>
        <?supplied-pmid 14962934?>
        <pub-id pub-id-type="pmid">14962934</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>LG</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>QY</given-names>
          </name>
        </person-group>
        <article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>
        <source>OMICS</source>
        <year>2012</year>
        <volume>16</volume>
        <fpage>284</fpage>
        <lpage>287</lpage>
        <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>
        <?supplied-pmid 22455463?>
        <pub-id pub-id-type="pmid">22455463</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hanzelmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Castelo</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Guinney</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>
        <source>BMC Bioinformatics</source>
        <year>2013</year>
        <volume>14</volume>
        <fpage>7</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id>
        <?supplied-pmid 23323831?>
        <pub-id pub-id-type="pmid">23323831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Subramanian</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mootha</surname>
            <given-names>VK</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ebert</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Paulovich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pomeroy</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Golub</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Lander</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>JP</given-names>
          </name>
        </person-group>
        <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2005</year>
        <volume>102</volume>
        <fpage>15545</fpage>
        <lpage>15550</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>
        <?supplied-pmid 16199517?>
        <pub-id pub-id-type="pmid">16199517</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Pathway enrichment analysis approach based on topological structure and updated annotation of pathway</article-title>
        <source>Brief Bioinform</source>
        <year>2019</year>
        <volume>20</volume>
        <fpage>168</fpage>
        <lpage>177</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbx091</pub-id>
        <?supplied-pmid 28968630?>
        <pub-id pub-id-type="pmid">28968630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>CePa: an R package for finding significant pathways weighted by multiple network centralities</article-title>
        <source>Bioinformatics</source>
        <year>2013</year>
        <volume>29</volume>
        <fpage>658</fpage>
        <lpage>660</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btt008</pub-id>
        <?supplied-pmid 23314125?>
        <pub-id pub-id-type="pmid">23314125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tarca</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Draghici</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Khatri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hassan</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Mittal</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Kusanovic</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Romero</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>A novel signaling pathway impact analysis</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>75</fpage>
        <lpage>82</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn577</pub-id>
        <?supplied-pmid 18990722?>
        <pub-id pub-id-type="pmid">18990722</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bayerlova</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kramer</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Klemm</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bleckmann</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Beissbarth</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Comparative study on gene set and pathway topology-based enrichment methods</article-title>
        <source>BMC Bioinformatics</source>
        <year>2015</year>
        <volume>16</volume>
        <fpage>334</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-015-0751-5</pub-id>
        <?supplied-pmid 26489510?>
        <pub-id pub-id-type="pmid">26489510</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jeong</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Ro</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>KY</given-names>
          </name>
        </person-group>
        <article-title>Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway</article-title>
        <source>NPJ Precis Oncol</source>
        <year>2018</year>
        <volume>2</volume>
        <fpage>5</fpage>
        <pub-id pub-id-type="doi">10.1038/s41698-018-0049-y</pub-id>
        <?supplied-pmid 29872723?>
        <pub-id pub-id-type="pmid">29872723</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pham</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Christadore</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Schaus</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kolaczyk</surname>
            <given-names>ED</given-names>
          </name>
        </person-group>
        <article-title>Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2011</year>
        <volume>108</volume>
        <fpage>13347</fpage>
        <lpage>13352</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1100891108</pub-id>
        <?supplied-pmid 21788508?>
        <pub-id pub-id-type="pmid">21788508</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dutta</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Wallqvist</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Reifman</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>PathNet: a tool for pathway analysis using topological information</article-title>
        <source>Source Code Biol Med</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>10</fpage>
        <pub-id pub-id-type="doi">10.1186/1751-0473-7-10</pub-id>
        <?supplied-pmid 23006764?>
        <pub-id pub-id-type="pmid">23006764</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Agarwal</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rajagopalan</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>A global pathway crosstalk network</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>1442</fpage>
        <lpage>1447</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn200</pub-id>
        <?supplied-pmid 18434343?>
        <pub-id pub-id-type="pmid">18434343</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>ZP</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>XS</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer’s disease brains</article-title>
        <source>BMC Syst Biol</source>
        <year>2010</year>
        <volume>4</volume>
        <issue>Suppl 2</issue>
        <fpage>S11</fpage>
        <pub-id pub-id-type="doi">10.1186/1752-0509-4-S2-S11</pub-id>
        <?supplied-pmid 20840725?>
        <pub-id pub-id-type="pmid">20840725</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kelder</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Eijssen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kleemann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>van Erk</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kooistra</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Evelo</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Exploring pathway interactions in insulin resistant mouse liver</article-title>
        <source>BMC Syst Biol</source>
        <year>2011</year>
        <volume>5</volume>
        <fpage>127</fpage>
        <pub-id pub-id-type="doi">10.1186/1752-0509-5-127</pub-id>
        <?supplied-pmid 21843341?>
        <pub-id pub-id-type="pmid">21843341</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fabregat</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Jupe</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Matthews</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Sidiropoulos</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Garapati</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Haw</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jassal</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Korninger</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>May</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The reactome pathway knowledgebase</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D649</fpage>
        <lpage>D655</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1132</pub-id>
        <?supplied-pmid 29145629?>
        <pub-id pub-id-type="pmid">29145629</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>PANTHER pathway: an ontology-based pathway database coupled with data analysis tools</article-title>
        <source>Methods Mol Biol</source>
        <year>2009</year>
        <volume>563</volume>
        <fpage>123</fpage>
        <lpage>140</lpage>
        <pub-id pub-id-type="doi">10.1007/978-1-60761-175-2_7</pub-id>
        <?supplied-pmid 19597783?>
        <pub-id pub-id-type="pmid">19597783</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Romero</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wagg</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Kaiser</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Krummenacker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Karp</surname>
            <given-names>PD</given-names>
          </name>
        </person-group>
        <article-title>Computational prediction of human metabolic pathways from the complete human genome</article-title>
        <source>Genome Biol</source>
        <year>2005</year>
        <volume>6</volume>
        <fpage>R2</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2004-6-1-r2</pub-id>
        <?supplied-pmid 15642094?>
        <pub-id pub-id-type="pmid">15642094</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sakai</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Fukagawa</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Fukuda</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Takagi</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>INOH: ontology-based highly structured database of signal transduction pathways</article-title>
        <source>Database (Oxford)</source>
        <year>2011</year>
        <volume>2011</volume>
        <fpage>bar052</fpage>
        <pub-id pub-id-type="doi">10.1093/database/bar052</pub-id>
        <pub-id pub-id-type="pmid">22120663</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kandasamy</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mohan</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Raju</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Keerthikumar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>GS</given-names>
          </name>
          <name>
            <surname>Venugopal</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Telikicherla</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Navarro</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Mathivanan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pecquet</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NetPath: a public resource of curated signal transduction pathways</article-title>
        <source>Genome Biol</source>
        <year>2010</year>
        <volume>11</volume>
        <fpage>R3</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2010-11-1-r3</pub-id>
        <?supplied-pmid 20067622?>
        <pub-id pub-id-type="pmid">20067622</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schaefer</surname>
            <given-names>CF</given-names>
          </name>
          <name>
            <surname>Anthony</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Krupa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Buchoff</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Day</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hannay</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Buetow</surname>
            <given-names>KH</given-names>
          </name>
        </person-group>
        <article-title>PID: the pathway interaction database</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>D674</fpage>
        <lpage>D679</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkn653</pub-id>
        <?supplied-pmid 18832364?>
        <pub-id pub-id-type="pmid">18832364</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Slenter</surname>
            <given-names>DN</given-names>
          </name>
          <name>
            <surname>Kutmon</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hanspers</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Riutta</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Windsor</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nunes</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Melius</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cirillo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Coort</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Digles</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D661</fpage>
        <lpage>D667</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1064</pub-id>
        <?supplied-pmid 29136241?>
        <pub-id pub-id-type="pmid">29136241</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mitra</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Long</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Eischen</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <source>CTpathway: a crosstalk-based pathway enrichment analysis method</source>
        <year>2022</year>
        <publisher-name>Github</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rodchenkov</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Babur</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Luna</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Fong</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Franz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Siper</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wrana</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pathway Commons 2019 Update: integration, analysis and exploration of pathway data</article-title>
        <source>Nucleic Acids Res</source>
        <year>2020</year>
        <volume>48</volume>
        <fpage>D489</fpage>
        <lpage>D497</lpage>
        <?supplied-pmid 31647099?>
        <pub-id pub-id-type="pmid">31647099</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Miao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>SubpathwayMiner: a software package for flexible identification of pathways</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>e131</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkp667</pub-id>
        <?supplied-pmid 19706733?>
        <pub-id pub-id-type="pmid">19706733</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mohamed</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hancock</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Mamitsuka</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>NetPathMiner: R/Bioconductor package for network path mining through gene expression</article-title>
        <source>Bioinformatics</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>3139</fpage>
        <lpage>3141</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu501</pub-id>
        <?supplied-pmid 25075120?>
        <pub-id pub-id-type="pmid">25075120</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Matys</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Fricke</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Geffers</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gossling</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Haubrock</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hehl</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hornischer</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Karas</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kel</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Kel-Margoulis</surname>
            <given-names>OV</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TRANSFAC: transcriptional regulation, from patterns to profiles</article-title>
        <source>Nucleic Acids Res</source>
        <year>2003</year>
        <volume>31</volume>
        <fpage>374</fpage>
        <lpage>378</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkg108</pub-id>
        <?supplied-pmid 12520026?>
        <pub-id pub-id-type="pmid">12520026</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Handy</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schneeweiss</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Barabasi</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Loscalzo</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Network-based approach to prediction and population-based validation of in silico drug repurposing</article-title>
        <source>Nat Commun</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>2691</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-05116-5</pub-id>
        <?supplied-pmid 30002366?>
        <pub-id pub-id-type="pmid">30002366</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kovacs</surname>
            <given-names>IA</given-names>
          </name>
          <name>
            <surname>Barabasi</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>Network-based prediction of drug combinations</article-title>
        <source>Nat Commun</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>1197</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-019-09186-x</pub-id>
        <?supplied-pmid 30867426?>
        <pub-id pub-id-type="pmid">30867426</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tarca</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Draghici</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bhatti</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Romero</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Down-weighting overlapping genes improves gene set analysis</article-title>
        <source>BMC Bioinformatics</source>
        <year>2012</year>
        <volume>13</volume>
        <fpage>136</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2105-13-136</pub-id>
        <?supplied-pmid 22713124?>
        <pub-id pub-id-type="pmid">22713124</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zyla</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Marczyk</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Domaszewska</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kaufmann</surname>
            <given-names>SHE</given-names>
          </name>
          <name>
            <surname>Polanska</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weiner</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Gene set enrichment for reproducible science: comparison of CERNO and eight other algorithms</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <fpage>5146</fpage>
        <lpage>5154</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btz447</pub-id>
        <?supplied-pmid 31165139?>
        <pub-id pub-id-type="pmid">31165139</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barrett</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Wilhite</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Ledoux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Evangelista</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>IF</given-names>
          </name>
          <name>
            <surname>Tomashevsky</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Marshall</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Phillippy</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Holko</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NCBI GEO: archive for functional genomics data sets--update</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>D991</fpage>
        <lpage>D995</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id>
        <?supplied-pmid 23193258?>
        <pub-id pub-id-type="pmid">23193258</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomczak</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Czerwinska</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wiznerowicz</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>
        <source>Contemp Oncol (Pozn)</source>
        <year>2015</year>
        <volume>19</volume>
        <fpage>A68</fpage>
        <lpage>A77</lpage>
        <pub-id pub-id-type="pmid">25691825</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szigeti</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Kalmar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Galamb</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Valcz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bartak</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Nagy</surname>
            <given-names>ZB</given-names>
          </name>
          <name>
            <surname>Zsigrai</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Felletar</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Patai</surname>
            <given-names>ÁV</given-names>
          </name>
          <name>
            <surname>Micsik</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Global DNA hypomethylation of colorectal tumours detected in tissue and liquid biopsies may be related to decreased methyl-donor content</article-title>
        <source>BMC Cancer</source>
        <year>2022</year>
        <volume>22</volume>
        <fpage>605</fpage>
        <pub-id pub-id-type="doi">10.1186/s12885-022-09659-1</pub-id>
        <?supplied-pmid 35655145?>
        <pub-id pub-id-type="pmid">35655145</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Sen-Yung</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <source>Gene expression profile of hepatocellular carcinoma patients in Taiwan</source>
        <year>2019</year>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Moreno Leon</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gautier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Allan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ilie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nottet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Pons</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Paquet</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lebrigand</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Truchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fassy</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress</article-title>
        <source>Oncogene</source>
        <year>2019</year>
        <volume>38</volume>
        <fpage>7146</fpage>
        <lpage>7165</lpage>
        <pub-id pub-id-type="doi">10.1038/s41388-019-0935-y</pub-id>
        <?supplied-pmid 31417181?>
        <pub-id pub-id-type="pmid">31417181</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tothill</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Tinker</surname>
            <given-names>AV</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Fox</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Lade</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Trivett</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Etemadmoghadam</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Locandro</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome</article-title>
        <source>Clin Cancer Res</source>
        <year>2008</year>
        <volume>14</volume>
        <fpage>5198</fpage>
        <lpage>5208</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0196</pub-id>
        <?supplied-pmid 18698038?>
        <pub-id pub-id-type="pmid">18698038</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rotunno</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Goldstein</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Bergen</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Consonni</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pesatori</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Bertazzi</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Wacholder</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma</article-title>
        <source>Cancer Prev Res (Phila)</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>1599</fpage>
        <lpage>1608</lpage>
        <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-10-0170</pub-id>
        <pub-id pub-id-type="pmid">21742797</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karaayvaz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cristea</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Mylvaganam</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Specht</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Bernstein</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Michor</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ellisen</surname>
            <given-names>LW</given-names>
          </name>
        </person-group>
        <article-title>Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq</article-title>
        <source>Nat Commun</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>3588</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-06052-0</pub-id>
        <?supplied-pmid 30181541?>
        <pub-id pub-id-type="pmid">30181541</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Phipson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>GK</given-names>
          </name>
        </person-group>
        <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>e47</fpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
        <?supplied-pmid 25605792?>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Love</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Huber</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Anders</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>
        <source>Genome Biol</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>550</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
        <?supplied-pmid 25516281?>
        <pub-id pub-id-type="pmid">25516281</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mitra</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Greenawalt</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Maulik</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Eischen</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>1604</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-017-01781-0</pub-id>
        <?supplied-pmid 29150601?>
        <pub-id pub-id-type="pmid">29150601</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stuart</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hoffman</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hafemeister</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Papalexi</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mauck</surname>
            <given-names>WM</given-names>
            <suffix>3rd</suffix>
          </name>
          <name>
            <surname>Hao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Stoeckius</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Smibert</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Satija</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Comprehensive integration of single-cell data</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>177</volume>
        <fpage>1888</fpage>
        <lpage>1902.e1821</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id>
        <?supplied-pmid 31178118?>
        <pub-id pub-id-type="pmid">31178118</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McCarthy</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>GK</given-names>
          </name>
        </person-group>
        <article-title>Testing significance relative to a fold-change threshold is a TREAT</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>765</fpage>
        <lpage>771</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp053</pub-id>
        <?supplied-pmid 19176553?>
        <pub-id pub-id-type="pmid">19176553</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hsiao</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Suresh</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>HI</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>A novel significance score for gene selection and ranking</article-title>
        <source>Bioinformatics</source>
        <year>2014</year>
        <volume>30</volume>
        <fpage>801</fpage>
        <lpage>807</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr671</pub-id>
        <?supplied-pmid 22321699?>
        <pub-id pub-id-type="pmid">22321699</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rosvall</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bergstrom</surname>
            <given-names>CT</given-names>
          </name>
        </person-group>
        <article-title>Maps of random walks on complex networks reveal community structure</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2008</year>
        <volume>105</volume>
        <fpage>1118</fpage>
        <lpage>1123</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0706851105</pub-id>
        <?supplied-pmid 18216267?>
        <pub-id pub-id-type="pmid">18216267</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Knijnenburg</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Wessels</surname>
            <given-names>LF</given-names>
          </name>
          <name>
            <surname>Reinders</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Shmulevich</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Fewer permutations, more accurate P-values</article-title>
        <source>Bioinformatics</source>
        <year>2009</year>
        <volume>25</volume>
        <fpage>i161</fpage>
        <lpage>i168</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp211</pub-id>
        <?supplied-pmid 19477983?>
        <pub-id pub-id-type="pmid">19477983</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Benjamini</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Drai</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Elmer</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kafkafi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Golani</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Controlling the false discovery rate in behavior genetics research</article-title>
        <source>Behav Brain Res</source>
        <year>2001</year>
        <volume>125</volume>
        <fpage>279</fpage>
        <lpage>284</lpage>
        <pub-id pub-id-type="doi">10.1016/S0166-4328(01)00297-2</pub-id>
        <?supplied-pmid 11682119?>
        <pub-id pub-id-type="pmid">11682119</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Enright</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Van Dongen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ouzounis</surname>
            <given-names>CA</given-names>
          </name>
        </person-group>
        <article-title>An efficient algorithm for large-scale detection of protein families</article-title>
        <source>Nucleic Acids Res</source>
        <year>2002</year>
        <volume>30</volume>
        <fpage>1575</fpage>
        <lpage>1584</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/30.7.1575</pub-id>
        <?supplied-pmid 11917018?>
        <pub-id pub-id-type="pmid">11917018</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Kurtyka</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rawal</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Fulp</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Haura</surname>
            <given-names>EB</given-names>
          </name>
          <name>
            <surname>Cress</surname>
            <given-names>WD</given-names>
          </name>
        </person-group>
        <article-title>Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions</article-title>
        <source>J Biol Chem</source>
        <year>2012</year>
        <volume>287</volume>
        <fpage>40106</fpage>
        <lpage>40118</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M112.380865</pub-id>
        <?supplied-pmid 23060449?>
        <pub-id pub-id-type="pmid">23060449</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ito</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Miki</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Saito</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Inoue</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Okada</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sasano</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Amyloid precursor protein and its phosphorylated form in non-small cell lung carcinoma</article-title>
        <source>Pathol Res Pract</source>
        <year>2019</year>
        <volume>215</volume>
        <fpage>152463</fpage>
        <pub-id pub-id-type="doi">10.1016/j.prp.2019.152463</pub-id>
        <?supplied-pmid 31138460?>
        <pub-id pub-id-type="pmid">31138460</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Siegfried</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Hershberger</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Stabile</surname>
            <given-names>LP</given-names>
          </name>
        </person-group>
        <article-title>Estrogen receptor signaling in lung cancer</article-title>
        <source>Semin Oncol</source>
        <year>2009</year>
        <volume>36</volume>
        <fpage>524</fpage>
        <lpage>531</lpage>
        <pub-id pub-id-type="doi">10.1053/j.seminoncol.2009.10.004</pub-id>
        <?supplied-pmid 19995644?>
        <pub-id pub-id-type="pmid">19995644</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Cancer Genome Atlas Research N</collab>
        </person-group>
        <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>511</volume>
        <fpage>543</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="doi">10.1038/nature13385</pub-id>
        <pub-id pub-id-type="pmid">25079552</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sondka</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Bamford</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Ward</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Dunham</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Forbes</surname>
            <given-names>SA</given-names>
          </name>
        </person-group>
        <article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title>
        <source>Nat Rev Cancer</source>
        <year>2018</year>
        <volume>18</volume>
        <fpage>696</fpage>
        <lpage>705</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-018-0060-1</pub-id>
        <?supplied-pmid 30293088?>
        <pub-id pub-id-type="pmid">30293088</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zandi</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>AP-1 function and regulation</article-title>
        <source>Curr Opin Cell Biol</source>
        <year>1997</year>
        <volume>9</volume>
        <fpage>240</fpage>
        <lpage>246</lpage>
        <pub-id pub-id-type="doi">10.1016/S0955-0674(97)80068-3</pub-id>
        <?supplied-pmid 9069263?>
        <pub-id pub-id-type="pmid">9069263</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Angel</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Karin</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation</article-title>
        <source>Biochim Biophys Acta</source>
        <year>1991</year>
        <volume>1072</volume>
        <fpage>129</fpage>
        <lpage>157</lpage>
        <?supplied-pmid 1751545?>
        <pub-id pub-id-type="pmid">1751545</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ameyar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wisniewska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Weitzman</surname>
            <given-names>JB</given-names>
          </name>
        </person-group>
        <article-title>A role for AP-1 in apoptosis: the case for and against</article-title>
        <source>Biochimie</source>
        <year>2003</year>
        <volume>85</volume>
        <fpage>747</fpage>
        <lpage>752</lpage>
        <pub-id pub-id-type="doi">10.1016/j.biochi.2003.09.006</pub-id>
        <?supplied-pmid 14585541?>
        <pub-id pub-id-type="pmid">14585541</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ibrahim</surname>
            <given-names>SAE</given-names>
          </name>
          <name>
            <surname>Abudu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Aftab</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Conrad</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Fluck</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>The role of AP-1 in self-sufficient proliferation and migration of cancer cells and its potential impact on an autocrine/paracrine loop</article-title>
        <source>Oncotarget</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>34259</fpage>
        <lpage>34278</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.26047</pub-id>
        <?supplied-pmid 30344941?>
        <pub-id pub-id-type="pmid">30344941</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lopez-Bergami</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lau</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ronai</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Emerging roles of ATF2 and the dynamic AP1 network in cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2010</year>
        <volume>10</volume>
        <fpage>65</fpage>
        <lpage>76</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc2681</pub-id>
        <?supplied-pmid 20029425?>
        <pub-id pub-id-type="pmid">20029425</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szabo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Riffe</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Steinberg</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Birrer</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Linnoila</surname>
            <given-names>RI</given-names>
          </name>
        </person-group>
        <article-title>Altered cJUN expression: an early event in human lung carcinogenesis</article-title>
        <source>Cancer Res</source>
        <year>1996</year>
        <volume>56</volume>
        <fpage>305</fpage>
        <lpage>315</lpage>
        <?supplied-pmid 8542585?>
        <pub-id pub-id-type="pmid">8542585</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tessari</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ferrara</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Poletti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dubrovich</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Corsini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Del Favero</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Naccarato</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>The expression of proto-oncogene c-jun in human pancreatic cancer</article-title>
        <source>Anticancer Res</source>
        <year>1999</year>
        <volume>19</volume>
        <fpage>863</fpage>
        <lpage>867</lpage>
        <?supplied-pmid 10216507?>
        <pub-id pub-id-type="pmid">10216507</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gartel</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>FOXM1 in cancer: interactions and vulnerabilities</article-title>
        <source>Cancer Res</source>
        <year>2017</year>
        <volume>77</volume>
        <fpage>3135</fpage>
        <lpage>3139</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3566</pub-id>
        <?supplied-pmid 28584182?>
        <pub-id pub-id-type="pmid">28584182</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Najafi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Farhood</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mortezaee</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Extracellular matrix (ECM) stiffness and degradation as cancer drivers</article-title>
        <source>J Cell Biochem</source>
        <year>2019</year>
        <volume>120</volume>
        <fpage>2782</fpage>
        <lpage>2790</lpage>
        <pub-id pub-id-type="doi">10.1002/jcb.27681</pub-id>
        <?supplied-pmid 30321449?>
        <pub-id pub-id-type="pmid">30321449</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kessenbrock</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Plaks</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Werb</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Matrix metalloproteinases: regulators of the tumor microenvironment</article-title>
        <source>Cell</source>
        <year>2010</year>
        <volume>141</volume>
        <fpage>52</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2010.03.015</pub-id>
        <?supplied-pmid 20371345?>
        <pub-id pub-id-type="pmid">20371345</pub-id>
      </element-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tenen</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Chai</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>JL</given-names>
          </name>
        </person-group>
        <article-title>Metabolic alterations and vulnerabilities in hepatocellular carcinoma</article-title>
        <source>Gastroenterol Rep (Oxf)</source>
        <year>2021</year>
        <volume>9</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1093/gastro/goaa066</pub-id>
        <pub-id pub-id-type="pmid">33747521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nordgaard</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mortensen</surname>
            <given-names>PB</given-names>
          </name>
        </person-group>
        <article-title>Digestive processes in the human colon</article-title>
        <source>Nutrition</source>
        <year>1995</year>
        <volume>11</volume>
        <fpage>37</fpage>
        <lpage>45</lpage>
        <?supplied-pmid 7749242?>
        <pub-id pub-id-type="pmid">7749242</pub-id>
      </element-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Prutki</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Poljak-Blazi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jakopovic</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tomas</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Stipancic</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Zarkovic</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer</article-title>
        <source>Cancer Lett</source>
        <year>2006</year>
        <volume>238</volume>
        <fpage>188</fpage>
        <lpage>196</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2005.07.001</pub-id>
        <?supplied-pmid 16111806?>
        <pub-id pub-id-type="pmid">16111806</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Moon</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Soria</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Jang</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Obaidul Hoque</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sibony</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Trink</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>YS</given-names>
          </name>
          <name>
            <surname>Sidransky</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Involvement of aquaporins in colorectal carcinogenesis</article-title>
        <source>Oncogene</source>
        <year>2003</year>
        <volume>22</volume>
        <fpage>6699</fpage>
        <lpage>6703</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.onc.1206762</pub-id>
        <?supplied-pmid 14555983?>
        <pub-id pub-id-type="pmid">14555983</pub-id>
      </element-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients</article-title>
        <source>Oncol Lett</source>
        <year>2018</year>
        <volume>15</volume>
        <fpage>9110</fpage>
        <lpage>9116</lpage>
        <?supplied-pmid 29805642?>
        <pub-id pub-id-type="pmid">29805642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Prentki</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Madiraju</surname>
            <given-names>SR</given-names>
          </name>
        </person-group>
        <article-title>Glycerolipid metabolism and signaling in health and disease</article-title>
        <source>Endocr Rev</source>
        <year>2008</year>
        <volume>29</volume>
        <fpage>647</fpage>
        <lpage>676</lpage>
        <pub-id pub-id-type="doi">10.1210/er.2008-0007</pub-id>
        <?supplied-pmid 18606873?>
        <pub-id pub-id-type="pmid">18606873</pub-id>
      </element-citation>
    </ref>
    <ref id="CR77">
      <label>77.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schug</surname>
            <given-names>ZT</given-names>
          </name>
          <name>
            <surname>Vande Voorde</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gottlieb</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>The metabolic fate of acetate in cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2016</year>
        <volume>16</volume>
        <fpage>708</fpage>
        <lpage>717</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc.2016.87</pub-id>
        <?supplied-pmid 27562461?>
        <pub-id pub-id-type="pmid">27562461</pub-id>
      </element-citation>
    </ref>
    <ref id="CR78">
      <label>78.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Saab</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mallam</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>GA</given-names>
            <suffix>2nd</suffix>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>Impact of coffee on liver diseases: a systematic review</article-title>
        <source>Liver Int</source>
        <year>2014</year>
        <volume>34</volume>
        <fpage>495</fpage>
        <lpage>504</lpage>
        <pub-id pub-id-type="doi">10.1111/liv.12304</pub-id>
        <?supplied-pmid 24102757?>
        <pub-id pub-id-type="pmid">24102757</pub-id>
      </element-citation>
    </ref>
    <ref id="CR79">
      <label>79.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramsey</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Butnor</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Leclair</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>van der Velden</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lian</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kinsey</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Loss of RUNX1 is associated with aggressive lung adenocarcinomas</article-title>
        <source>J Cell Physiol</source>
        <year>2018</year>
        <volume>233</volume>
        <fpage>3487</fpage>
        <lpage>3497</lpage>
        <pub-id pub-id-type="doi">10.1002/jcp.26201</pub-id>
        <?supplied-pmid 28926105?>
        <pub-id pub-id-type="pmid">28926105</pub-id>
      </element-citation>
    </ref>
    <ref id="CR80">
      <label>80.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Westhoff</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Colaluca</surname>
            <given-names>IN</given-names>
          </name>
          <name>
            <surname>D'Ario</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Donzelli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tosoni</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Volorio</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pelosi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Spaggiari</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Mazzarol</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Viale</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Alterations of the Notch pathway in lung cancer</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2009</year>
        <volume>106</volume>
        <fpage>22293</fpage>
        <lpage>22298</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0907781106</pub-id>
        <?supplied-pmid 20007775?>
        <pub-id pub-id-type="pmid">20007775</pub-id>
      </element-citation>
    </ref>
    <ref id="CR81">
      <label>81.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Coukos</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tanyi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kandalaft</surname>
            <given-names>LE</given-names>
          </name>
        </person-group>
        <article-title>Opportunities in immunotherapy of ovarian cancer</article-title>
        <source>Ann Oncol</source>
        <year>2016</year>
        <volume>27</volume>
        <issue>Suppl 1</issue>
        <fpage>i11</fpage>
        <lpage>i15</lpage>
        <pub-id pub-id-type="doi">10.1093/annonc/mdw084</pub-id>
        <?supplied-pmid 27141063?>
        <pub-id pub-id-type="pmid">27141063</pub-id>
      </element-citation>
    </ref>
    <ref id="CR82">
      <label>82.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shanmughapriya</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Senthilkumar</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Vinodhini</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Das</surname>
            <given-names>BC</given-names>
          </name>
          <name>
            <surname>Vasanthi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Natarajaseenivasan</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Viral and bacterial aetiologies of epithelial ovarian cancer</article-title>
        <source>Eur J Clin Microbiol Infect Dis</source>
        <year>2012</year>
        <volume>31</volume>
        <fpage>2311</fpage>
        <lpage>2317</lpage>
        <pub-id pub-id-type="doi">10.1007/s10096-012-1570-5</pub-id>
        <?supplied-pmid 22402815?>
        <pub-id pub-id-type="pmid">22402815</pub-id>
      </element-citation>
    </ref>
    <ref id="CR83">
      <label>83.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Keikha</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Esfahani</surname>
            <given-names>BN</given-names>
          </name>
        </person-group>
        <article-title>The relationship between tuberculosis and lung cancer</article-title>
        <source>Adv Biomed Res</source>
        <year>2018</year>
        <volume>7</volume>
        <fpage>58</fpage>
        <pub-id pub-id-type="doi">10.4103/abr.abr_182_17</pub-id>
        <?supplied-pmid 29657943?>
        <pub-id pub-id-type="pmid">29657943</pub-id>
      </element-citation>
    </ref>
    <ref id="CR84">
      <label>84.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dy</surname>
            <given-names>GK</given-names>
          </name>
        </person-group>
        <article-title>The role of focal adhesion kinase in lung cancer</article-title>
        <source>Anticancer Agents Med Chem</source>
        <year>2013</year>
        <volume>13</volume>
        <fpage>581</fpage>
        <lpage>583</lpage>
        <pub-id pub-id-type="doi">10.2174/1871520611313040007</pub-id>
        <?supplied-pmid 22934708?>
        <pub-id pub-id-type="pmid">22934708</pub-id>
      </element-citation>
    </ref>
    <ref id="CR85">
      <label>85.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stevens</surname>
            <given-names>LE</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>WKC</given-names>
          </name>
          <name>
            <surname>Adua</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Arnal-Estape</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Brewer</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Herbst</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>DX</given-names>
          </name>
        </person-group>
        <article-title>Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases</article-title>
        <source>Cancer Res</source>
        <year>2017</year>
        <volume>77</volume>
        <fpage>1905</fpage>
        <lpage>1917</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1978</pub-id>
        <?supplied-pmid 28196904?>
        <pub-id pub-id-type="pmid">28196904</pub-id>
      </element-citation>
    </ref>
    <ref id="CR86">
      <label>86.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Burotto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chiou</surname>
            <given-names>VL</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Kohn</surname>
            <given-names>EC</given-names>
          </name>
        </person-group>
        <article-title>The MAPK pathway across different malignancies: a new perspective</article-title>
        <source>Cancer</source>
        <year>2014</year>
        <volume>120</volume>
        <fpage>3446</fpage>
        <lpage>3456</lpage>
        <pub-id pub-id-type="doi">10.1002/cncr.28864</pub-id>
        <?supplied-pmid 24948110?>
        <pub-id pub-id-type="pmid">24948110</pub-id>
      </element-citation>
    </ref>
    <ref id="CR87">
      <label>87.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bast</surname>
            <given-names>RC</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Hennessy</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>GB</given-names>
          </name>
        </person-group>
        <article-title>The biology of ovarian cancer: new opportunities for translation</article-title>
        <source>Nat Rev Cancer</source>
        <year>2009</year>
        <volume>9</volume>
        <fpage>415</fpage>
        <lpage>428</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc2644</pub-id>
        <?supplied-pmid 19461667?>
        <pub-id pub-id-type="pmid">19461667</pub-id>
      </element-citation>
    </ref>
    <ref id="CR88">
      <label>88.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arend</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Londono-Joshi</surname>
            <given-names>AI</given-names>
          </name>
          <name>
            <surname>Straughn</surname>
            <given-names>JM</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Buchsbaum</surname>
            <given-names>DJ</given-names>
          </name>
        </person-group>
        <article-title>The Wnt/beta-catenin pathway in ovarian cancer: a review</article-title>
        <source>Gynecol Oncol</source>
        <year>2013</year>
        <volume>131</volume>
        <fpage>772</fpage>
        <lpage>779</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ygyno.2013.09.034</pub-id>
        <?supplied-pmid 24125749?>
        <pub-id pub-id-type="pmid">24125749</pub-id>
      </element-citation>
    </ref>
    <ref id="CR89">
      <label>89.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Miao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Oliva</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wheeler</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hilsenbeck</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Orsulic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Goode</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Hippo pathway effector Yap is an ovarian cancer oncogene</article-title>
        <source>Cancer Res</source>
        <year>2010</year>
        <volume>70</volume>
        <fpage>8517</fpage>
        <lpage>8525</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1242</pub-id>
        <?supplied-pmid 20947521?>
        <pub-id pub-id-type="pmid">20947521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR90">
      <label>90.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Olea-Flores</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zuniga-Eulogio</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Mendoza-Catalan</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Rodriguez-Ruiz</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Castaneda-Saucedo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ortuno-Pineda</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Padilla-Benavides</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Navarro-Tito</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Extracellular-signal regulated kinase: a central molecule driving epithelial-mesenchymal transition in cancer</article-title>
        <source>Int J Mol Sci</source>
        <year>2019</year>
        <volume>20</volume>
        <issue>12</issue>
        <fpage>2885</fpage>
        <pub-id pub-id-type="doi">10.3390/ijms20122885</pub-id>
      </element-citation>
    </ref>
    <ref id="CR91">
      <label>91.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Buel</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Nagiec</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Roux</surname>
            <given-names>PP</given-names>
          </name>
          <name>
            <surname>Blenis</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yoon</surname>
            <given-names>SO</given-names>
          </name>
        </person-group>
        <article-title>ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2019</year>
        <volume>116</volume>
        <fpage>2967</fpage>
        <lpage>2976</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1811923116</pub-id>
        <?supplied-pmid 30728292?>
        <pub-id pub-id-type="pmid">30728292</pub-id>
      </element-citation>
    </ref>
    <ref id="CR92">
      <label>92.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Janiszewska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Primi</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Izard</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Cell adhesion in cancer: beyond the migration of single cells</article-title>
        <source>J Biol Chem</source>
        <year>2020</year>
        <volume>295</volume>
        <fpage>2495</fpage>
        <lpage>2505</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.REV119.007759</pub-id>
        <?supplied-pmid 31937589?>
        <pub-id pub-id-type="pmid">31937589</pub-id>
      </element-citation>
    </ref>
    <ref id="CR93">
      <label>93.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>dbEMT: an epithelial-mesenchymal transition associated gene resource</article-title>
        <source>Sci Rep</source>
        <year>2015</year>
        <volume>5</volume>
        <fpage>11459</fpage>
        <pub-id pub-id-type="doi">10.1038/srep11459</pub-id>
        <?supplied-pmid 26099468?>
        <pub-id pub-id-type="pmid">26099468</pub-id>
      </element-citation>
    </ref>
    <ref id="CR94">
      <label>94.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wallace</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Prueitt</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Yi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Howe</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Gillespie</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Yfantis</surname>
            <given-names>HG</given-names>
          </name>
          <name>
            <surname>Stephens</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Caporaso</surname>
            <given-names>NE</given-names>
          </name>
          <name>
            <surname>Loffredo</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Ambs</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Tumor immunobiological differences in prostate cancer between African-American and European-American men</article-title>
        <source>Cancer Res</source>
        <year>2008</year>
        <volume>68</volume>
        <fpage>927</fpage>
        <lpage>936</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2608</pub-id>
        <?supplied-pmid 18245496?>
        <pub-id pub-id-type="pmid">18245496</pub-id>
      </element-citation>
    </ref>
    <ref id="CR95">
      <label>95.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blalock</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Geddes</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Porter</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Markesbery</surname>
            <given-names>WR</given-names>
          </name>
          <name>
            <surname>Landfield</surname>
            <given-names>PW</given-names>
          </name>
        </person-group>
        <article-title>Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <year>2004</year>
        <volume>101</volume>
        <fpage>2173</fpage>
        <lpage>2178</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0308512100</pub-id>
        <?supplied-pmid 14769913?>
        <pub-id pub-id-type="pmid">14769913</pub-id>
      </element-citation>
    </ref>
    <ref id="CR96">
      <label>96.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dal Porto</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Gauld</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>Merrell</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pugh-Bernard</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Cambier</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>B cell antigen receptor signaling 101</article-title>
        <source>Mol Immunol</source>
        <year>2004</year>
        <volume>41</volume>
        <fpage>599</fpage>
        <lpage>613</lpage>
        <pub-id pub-id-type="doi">10.1016/j.molimm.2004.04.008</pub-id>
        <?supplied-pmid 15219998?>
        <pub-id pub-id-type="pmid">15219998</pub-id>
      </element-citation>
    </ref>
    <ref id="CR97">
      <label>97.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shibuya</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies</article-title>
        <source>Genes Cancer</source>
        <year>2011</year>
        <volume>2</volume>
        <fpage>1097</fpage>
        <lpage>1105</lpage>
        <pub-id pub-id-type="doi">10.1177/1947601911423031</pub-id>
        <?supplied-pmid 22866201?>
        <pub-id pub-id-type="pmid">22866201</pub-id>
      </element-citation>
    </ref>
    <ref id="CR98">
      <label>98.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sanjuan</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Dillon</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Tait</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Moshiach</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Dorsey</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Connell</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Komatsu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Cleveland</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Withoff</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>DR</given-names>
          </name>
        </person-group>
        <article-title>Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis</article-title>
        <source>Nature</source>
        <year>2007</year>
        <volume>450</volume>
        <fpage>1253</fpage>
        <lpage>1257</lpage>
        <pub-id pub-id-type="doi">10.1038/nature06421</pub-id>
        <?supplied-pmid 18097414?>
        <pub-id pub-id-type="pmid">18097414</pub-id>
      </element-citation>
    </ref>
    <ref id="CR99">
      <label>99.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gehmert</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lehoczky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Loibl</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Prantl</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gehmert</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Interaction between extracellular cancer matrix and stromal breast cells</article-title>
        <source>Clin Hemorheol Microcirc</source>
        <year>2020</year>
        <volume>74</volume>
        <fpage>45</fpage>
        <lpage>52</lpage>
        <pub-id pub-id-type="doi">10.3233/CH-199234</pub-id>
        <?supplied-pmid 31796667?>
        <pub-id pub-id-type="pmid">31796667</pub-id>
      </element-citation>
    </ref>
    <ref id="CR100">
      <label>100.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pitcher</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>van Oers</surname>
            <given-names>NS</given-names>
          </name>
        </person-group>
        <article-title>T-cell receptor signal transmission: who gives an ITAM?</article-title>
        <source>Trends Immunol</source>
        <year>2003</year>
        <volume>24</volume>
        <fpage>554</fpage>
        <lpage>560</lpage>
        <pub-id pub-id-type="doi">10.1016/j.it.2003.08.003</pub-id>
        <?supplied-pmid 14552840?>
        <pub-id pub-id-type="pmid">14552840</pub-id>
      </element-citation>
    </ref>
    <ref id="CR101">
      <label>101.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang da</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Lempicki</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>
        <source>Nat Protoc</source>
        <year>2009</year>
        <volume>4</volume>
        <fpage>44</fpage>
        <lpage>57</lpage>
        <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
        <?supplied-pmid 19131956?>
        <pub-id pub-id-type="pmid">19131956</pub-id>
      </element-citation>
    </ref>
    <ref id="CR102">
      <label>102.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Reimand</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Isserlin</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Voisin</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Kucera</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tannus-Lopes</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rostamianfar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wadi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap</article-title>
        <source>Nat Protoc</source>
        <year>2019</year>
        <volume>14</volume>
        <fpage>482</fpage>
        <lpage>517</lpage>
        <pub-id pub-id-type="doi">10.1038/s41596-018-0103-9</pub-id>
        <?supplied-pmid 30664679?>
        <pub-id pub-id-type="pmid">30664679</pub-id>
      </element-citation>
    </ref>
    <ref id="CR103">
      <label>103.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Trairatphisan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gjerga</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Didangelos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Barratt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Saez-Rodriguez</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL</article-title>
        <source>NPJ Syst Biol Appl</source>
        <year>2019</year>
        <volume>5</volume>
        <fpage>40</fpage>
        <pub-id pub-id-type="doi">10.1038/s41540-019-0118-z</pub-id>
        <?supplied-pmid 31728204?>
        <pub-id pub-id-type="pmid">31728204</pub-id>
      </element-citation>
    </ref>
    <ref id="CR104">
      <label>104.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garcia-Alonso</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Holland</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Ibrahim</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Turei</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Saez-Rodriguez</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Benchmark and integration of resources for the estimation of human transcription factor activities</article-title>
        <source>Genome Res</source>
        <year>2019</year>
        <volume>29</volume>
        <fpage>1363</fpage>
        <lpage>1375</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.240663.118</pub-id>
        <?supplied-pmid 31340985?>
        <pub-id pub-id-type="pmid">31340985</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
